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Abstract
CT Perfusion (CTP) is a minimally invasive imaging technique that aids acute ischemic
stroke (AIS) triage and prognostication by determining tissue viability based on hemodynamic
parameters. The goals of this research are to determine: 1) CTP thresholds for estimation of
infarct and penumbra volume, 2) how CTP scan duration impacts infarct and penumbra volume
estimates, and 3) reliability of CTP for predicting functional outcomes following intra-arterial
therapy (IAT).
Chapter 2 introduced an experimental study for determining ischemia-time dependent
thresholds for brain infarction using multimodal imaging in a porcine stroke model that is
easier to implement than previous large animal stroke models. CTP determined an absolute
cerebral blood flow (CBF) threshold of 12.6±2.8mL∙min-1∙100g-1 for brain infarction after 3h
of ischemia, which was close to that derived using hydrogen clearance in a previous study by
Jones et al (Journal of Neurosurgery, 1981;54(6):773-782).
Chapter 3 retrospectively investigated the impact of CTP scan duration on cerebral
blood volume (CBV), CBF, and time-to-maximum (Tmax) and found optimal scan durations
that minimized radiation dose while not under- or over-estimating infarct volumes measured
using two previously derived CBF thresholds for infarction. We found that CBV and Tmax
decreased at shorter scan durations, whereas CBF was independent of scan duration,
consequently, infarct volume estimated by both CBF thresholds was independent of scan
duration.
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Chapter 4 compared reperfusion seen on follow-up CTP to reperfusion predicted by
post-IAT digital subtraction angiography (DSA) and the ability of the two modalities to predict
good 90-day functional outcome in a retrospective study. We found that patients with
‘complete reperfusion’ grades on DSA often had ischemic tissue on follow-up CTP and that
follow-up CTP had superior specificity and accuracy for predicting functional outcome
compared to DSA.
In summary, this research has shown that CBF thresholds can reliably detect infarct in
AIS and are independent of scan duration, allowing radiation dose to be minimized by limiting
scans to 40s without compromising accuracy of infarct volume estimates. Finally, CTP is a
more specific and accurate predictor of functional outcome than the commonly used postprocedural DSA, this could help select patients for neuroprotective therapy.

Keywords
Stroke, cerebral ischemia, computed tomography, computed tomography perfusion, functional
imaging, cerebral blood flow, infarction, animal stroke model, mechanical thrombectomy.
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Chapter 1

1

Introduction
Stroke is the second leading cause of death, and third leading cause of disability

worldwide1 according to the World Health Organization. Overall, stroke mortality rates
have declined over the last 30 years in the United States2, and Canada3, but incidence
rates remain higher in certain racial4, and gender cohorts5, and in certain geographical
areas6. The decline in overall stroke mortality rate is due to a decrease in the number of
fatal strokes7, rather than a decrease in stroke incidence, which is projected to more than
double over the next 30 years, with most of the increase coming from people aged 75
years or older8. Approximately half the survivors of stroke are institutionalized or
disabled within 5 years9, and due to the aging population, the number of individuals
living with disability resulting from stroke is projected to almost double in the next 2
decades10. Long term care for these patients will further increase the socioeconomic
burden of cerebrovascular disease11. CT Perfusion (CTP) is a minimally invasive
imaging technique that produces quantitative maps of hemodynamic parameters which
can be used to assess tissue viability. CTP could improve outcomes after stroke by
allowing triaging based on each patients’ brain tissue viability, allowing the optimal
treatment to be selected on an individualized basis. Post treatment CTP is not commonly
performed but could also be used to improve prognostication by quantitatively assessing
reperfusion of ischemic tissue. The goals of this research are to determine: 1) CTP
thresholds for estimation of infarct and penumbra volume, 2) how CTP scan duration
impacts infarct and penumbra volume estimates, and 3) the prognostic utility of CTP for
predicting functional outcomes following intra-arterial therapy (IAT). To lessen the
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future socioeconomic burden of cerebrovascular disease, CTP-based acute treatment and
patient-specific triaging and management must be improved to reduce the proportion of
stroke patients living with severe disability following their stroke.

1.1 Stroke Pathophysiology
Stroke is caused by a reduction in blood flow to the brain and can be divided into
two broad categories. Hemorrhagic strokes are caused by leakage from damaged cerebral
blood vessels, and ischemic strokes are caused by blockage of an artery supplying the brain
tissue. This thesis deals only with ischemic stroke and not hemorrhagic stroke. Studies
suggest that the overall annual incidence of first-ever stroke in North America is 189 per
100,000 people, with ischemic strokes accounting for ~85% of the total incidence12.
Approximately 30% of ischemic stroke patients die within 3 months of the stroke13, and
~45% of survivors will not be able to live independently14.

1.1.1

Cerebral Ischemia
Cerebral ischemia is a condition where restricted cerebral blood flow (CBF) leads

to insufficient supply of oxygen and glucose to meet the metabolic demands of brain tissue.
Cerebral ischemia can be global, such as when cardiac arrest or open-heart surgery results
in complete cessation of systemic blood flow, or focal, where CBF is reduced in one region
of the brain15. There are multiple arterial etiologies of focal cerebral ischemia. The most
common are thrombosis in situ, clot formation in a cerebral artery due to endothelial injury
triggering the coagulation cascade; and thromboembolism, where emboli travel to cerebral
vessels through the blood after rupture of a thrombus or atherosclerotic plaque elsewhere
in the body16. Cerebral emboli are also formed in the heart due to blood becoming static
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during atrial fibrillation, or from coagulation following open heart surgery. Sustained
hypertension can lead to fibrinoid deposits within cerebral arterioles, which is often
associated with lacunar infarction16. Ischemia in tissue supplied by the distal part of the
cerebral vascular tree is referred to as watershed stroke. Watershed stroke is usually caused
by decreased mean arterial pressure in the internal carotid arteries (ICA) due to myocardial
dysfunction, systemic hypotension, or ICA stenosis17.
The trial of Org 10172 in acute stroke treatment (TOAST)18 established a
classification system which denoted five subtypes of ischemic stroke: large-artery
atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined
etiology, and stroke of undetermined etiology19. Strokes of different subtypes (as identified
by TOAST criteria) can have varying clot composition, size, and density, which can impact
stroke severity and response to acute treatment20,21. Regardless of vascular etiology,
reduced delivery of oxygen and glucose due to reduced CBF results in inadequate
production of adenosine triphosphate (ATP) by cellular respiration. Neuronal cells require
ATP for active, facilitated transport of Na+, K+ and other ions to maintain their resting
membrane potential, and for action potential propagation. Intracellular ATP stores are
exhausted within minutes post ictus, leading to loss of ionic homeostasis22, this is the first
step in a complex ‘ischemic cascade’ which ultimately leads to cell death caused mainly
by excitotoxicity, Ca2+ dysregulation, and oxidative/nitrative stress.
Anoxic depolarization due to influx of Na+, and failure of normal reuptake
mechanisms causes excessive accumulation of the excitotoxic neurotransmitter, glutamate,
in the extracellular space23.

This leads to overstimulation of ionotropic glutamate

receptors, resulting in a large influx of Ca2+, Na+, and water into neurons. Accumulation
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of intracellular Ca2+ is further exacerbated by other anion channels activated during
ischemia24–26, and failure of normal Ca2+ efflux mechanisms, such as the Na+/Ca2+
exchanger27. Influx of Ca2+ activates proteases, lipases, and nucleases28, and also leads to
increased production of reactive oxygen species29. These factors can trigger release of Ca2+
from the endoplasmic reticulum, as well as reactive oxygen species and enzymes from the
mitochondria30, further accelerating the death spiral. Continued build-up of metabolic,
oxidative, and nitrative stressors eventually lead to cell death by necrosis or apoptosis.
Glutamate excitotoxicity also expands the ischemic injury at a macroscopic level by
causing cortical spreading depolarization, where elevated extracellular glutamate and K+
cause slowly propagating depolarization of surrounding neurons and astrocytes, and
disruption of ionic gradients31. Disruption of ionic gradients, and mismatch between
reduced CBF and high metabolic demand to support membrane repolarization lead to
expansion of the initial ischemic injury32.
Cerebral blood vessels are separated from brain tissue by a selectively permeable
barrier called the blood-brain barrier (BBB) which tightly regulates the passage of
molecules between the blood and brain tissue. The BBB consists of endothelial cells,
astrocytic end-feet, pericytes and a basement membrane. Tight junctions between adjacent
endothelial cells and astrocytic end-feet form a physical barrier, allowing lipophilic
molecules and metabolic products to cross by passive diffusion, and preventing diffusion
of hydrophilic molecules, and potential neurotoxins33. Pericytes embedded in the basement
membrane envelope the endothelial cells interact closely with them and play a role in
maintaining and regulating BBB function34. Prolonged ischemia triggers several responses
which compromise the integrity of the BBB. In the acute phase of stroke, ischemia causes
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pericytes to detach from endothelial cells, disrupting intercellular signalling interactions
which results in blood-borne substances entering the brain via increased endothelial
transcytosis35. Ischemia also degrades tight junctions between endothelial cells, allowing
molecules to travel out of the blood via paracellular diffusion36, and causes astrocytes to
retract their end-feet and release pro-inflammatory cytokines37. The longer the duration of
ischemia, the more severe the BBB breakdown and inflammatory response. This in turn
increases the likelihood of blood extravasation if the ischemic tissue is eventually
reperfused, a process known as hemorrhagic transformation of cerebral infarction.
Furthermore, hyperglycemia caused by diabetes mellitus is known to worsen BBB
breakdown, in addition to enhancing atherosclerosis, arterial stiffness, oxidative stress, and
systemic inflammation38. As a result, patients with diabetes mellitus are more likely to
have ischemic strokes, and also have higher rates of hemorrhagic transformation39 and
mortality 90 days post stroke40.
Tissue fate in ischemic stroke is time dependent (this will be detailed in the next
subsection); tissue remains viable after symptom onset, but ~1.9 million neurons become
irreversibly damaged every minute that stroke symptoms persist41. Treatment for acute
ischemic stroke (AIS) revolves around salvaging viable ischemic tissue by restoring normal
perfusion to the affected region as quickly as possible. However, restoring CBF to
ischemic tissue regions with a potentially compromised BBB can lead to hemorrhagic
transformation. For this reason, decisions surrounding the treatment of AIS are often
determined by weighing the potential benefits of reperfusion, which declines over time42,43,
against the risks of hemorrhagic transformation or other complications.
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1.1.2

Tissue Subtypes in Ischemic Stroke
In neuronal cells, the energy requirements, and by extension the CBF requirements,

for signal transduction (action potential propagation and neurotransmission) and
maintaining morphological integrity are different44. Consequently, tissue affected by focal
ischemia in the acute phase of ischemic stroke can be classified into distinct categories
based on blood flow thresholds. Studies show there are two critical thresholds of decreased
CBF: a threshold for reversible functional failure, and a lower threshold for irreversible
morphological damage45.
Tissue in the central, most hypoperfused region, with CBF below the threshold for
irreversible damage, is termed the infarct core. The definition of infarct core was originally
based on substantial increases in extracellular K+ concentration seen in baboons when CBF
was reduced by occlusion of the middle cerebral artery (MCA)45,46. Increased extracellular
K+ is a marker of anoxic depolarization, one of the early steps in the ischemic cascade
which ultimately leads to necrosis or apoptosis, therefore the infarct core is irreversibly
damaged and no longer viable, even with reperfusion. In cases where cerebral circulation
is completely arrested (e.g. cardiac arrest) brain infarction can occur within minutes, but
when cessation of blood flow is not complete the time it takes for infarction to occur
depends on the level of residual CBF. Experiments in animal models established that for
1 to 2 hours of ischemia, tissue with CBF less than 8-10 mL∙min-1∙100g-1 will become
infarcted47,48.
The tissue surrounding the infarct core, with CBF below the threshold for functional
failure, but above the threshold to induce acute infarction, is termed the penumbra. The
concept of penumbra was based on observations that electroencephalography activity was
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affected at a higher CBF level than the threshold for increased extracellular K+ in a baboon
model of focal ischemia45,46. Clinical49 and animal studies50,51 show that the CBF threshold
for functional impairment ranges from 15-20 mL∙min-1∙100g-1, depending on the species
and measurement method used. Tissue with CBF between the thresholds for functional
impairment and acute infarction will remain salvageable if normal blood flow is restored
promptly. As mentioned previously, the window for tissue viability before infarction
becomes inevitable depends on the level of residual blood flow and the duration of
ischemia52. The threshold for infarction after 1 hour of ischemia is ~8 mL∙min-1∙100g-1, if
ischemia persists for 3 hours the infarction threshold rises to ~12 mL∙min-1∙100g-1 47,48, if
normal CBF is not restored and ischemia persists indefinitely, then all penumbral tissue
will eventually progress to infarction48.
Lastly, tissue with CBF that is lower than normal levels but still above the threshold
for functional impairment is termed benign oligemia45. Despite hypoperfusion, this tissue
does not progress to infarction, regardless of the duration of ischemia, and is therefore not
as clinically important as infarct or penumbra.
The human brain is composed of two distinct types of tissue, gray and white matter.
Gray matter mainly consists of neuronal cell bodies, unmyelinated axons, glial cells and
synapses and is found in the cerebral cortex, thalamus, hypothalamus, and basal ganglia.
White matter consists of myelinated axons, and glial cells and connects various gray matter
regions together, allowing neuronal signals to be conducted through the brain quickly53.
Resting CBF is lower in white matter (20-25 mL∙min-1∙100g-1) than gray matter (50-60
mL∙min-1∙100g-1)54 because white matter consumes only about one third of the energy
consumed by gray matter due to greater efficiency conducting action potentials and the
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absence of synapses55. Since white matter has a lower energy demand and perfusion level,
it follows that CBF thresholds for infarction and electrical silence are also lower than in
gray matter for a given ischemia duration. Clinical studies have confirmed that the CBF
threshold for infarction in gray matter is significantly higher than in white matter for similar
ischemia durations56. Therefore, using the same infarction thresholds for both white and
gray matter may overestimate the volume of infarcted white matter56.

1.2 Treatment of Ischemic Stroke
Treatment of AIS was limited to medical management and basic life support until
the introduction of thrombolytic therapy in 199657. Current treatment of AIS is based on
recanalization of the occluded artery to restore CBF to ischemic tissue. There are two
approved treatment options: thrombolytic therapy – which works by dissolving the clot via
fibrinolysis, and mechanical thrombectomy – an interventional procedure where the clot is
mechanically removed using a specialized catheter58. Regardless of what treatment is used,
initiating therapy as soon as AIS is diagnosed by imaging is crucial for maximizing
penumbral salvage and lessening the risk of hemorrhagic transformation or other
complications42,43. Current clinical guidelines suggest implementing protocols such as prearrival hospital notification of incoming patients with possible AIS59, or using telemedicine
to accelerate image interpretation for rural centers without a neuroradiologist on site60, to
minimize the delay between hospital admission and initiation of treatment (referred to as
‘door-to-needle time’). The goal of implementing such protocols is to perform CT within
20 minutes of admission and keep door-to-needle times less than 60 minutes in at least
50% of patients61.
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1.2.1

Thrombolytic Therapy
Thrombus formation (thrombosis) and dissolution (thrombolysis) are complex

interconnected processes. Thrombosis starts when platelets are activated by contact with
sub-endothelial proteins62.

Activated platelets trigger a series of protease-mediated

cleavages which ultimately ends with the serine protease thrombin cleaving soluble
fibrinogen into insoluble fibrin63. Fibrin polymerizes to form the bulk of the blood clot
along with activated platelets, red blood cells, and white blood cells64. This clotting
cascade prevents excessive blood loss from damaged blood vessels but can also lead to
thromboembolic stroke when clots form in cerebral arteries, or travel to cerebral arteries
from elsewhere in the body. Clot dissolution is mediated by endogenous fibrinolysis,
which relies on the formation of plasmin, a fibrinolytic enzyme, from its precursor
plasminogen. This conversion is catalyzed by a group of enzymes called plasminogen
activators65.

Thrombolytic therapy involves administering drugs that are either

recombinant versions of endogenous plasminogen activators (e.g. tissue plasminogen
activator (t-PA) or urokinase-plasminogen activator (u-PA)), or exogenous plasminogen
activating agents (e.g. streptokinase), that enhance plasmin-mediated fibrinolysis65. The
likelihood of early recanalization and good outcome after IV thrombolysis is dependent on
the clot fibrin content66, and its length and density on CT67,68. Early vessel recanalization
and good functional outcome are also more likely in cardioembolic strokes compared to
other stroke subtypes69,70. A significant drawback to thrombolysis is that degradation of
fibrin and fibrinogen inhibits the coagulation cascade71, and therefore increases the risk of
intracerebral hemorrhage (ICH)72. Additionally, in patients with compromised BBB due
to prolonged ischemia, t-PA can cross into the interstitial space, where it has neurotoxic
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effects that can enhance excitotoxicity and further damage the BBB73. For this reason,
primary ICH must be ruled out by computed tomography (CT) or magnetic resonance
imaging (MRI) before initiating thrombolysis74.
The first clinical trial to show a significant benefit of thrombolytic therapy was the
National Institute of Neurological Disorders and Stroke (NINDS) trial in 1995. Alteplase,
a recombinant version of t-PA was administered intravenously within 3 hours of symptom
onset, in patients with no evidence of ICH on CT. The percentage of patients with excellent
outcome (assessed as a score of 0 or 1 on the modified Rankin Scale (mRS)) in the t-PA
group was 43% compared to only 26% in the control group, and 90 day mortality was also
lower in the t-PA group, despite increased risk of ICH (6.4% vs 0.6%)57. Based on these
results, the United States Food and Drug Administration (FDA) approved IV t-PA for the
treatment of AIS within 3 hours post symptom onset. Phase IV trials in Canada75 and
Europe76 would later confirm the efficacy of IV t-PA in routine care settings, showing that
rates of excellent outcome (mRS ≤ 1) (~38%), mortality within 90 days (11% to 22%), and
symptomatic ICH (~6%) were all similar to pooled results from randomized controlled
trials.
In the decade after FDA approval, administration rates of IV t-PA remained as low
as 0.9% to 2.4%77,78, with the 3 hour time window posing a significant barrier to
treatment79. Multiple trials comparing placebo to IV t-PA given within the first 6 hours
post onset80,81, or in the 3 to 5 hour time window82, failed to show a significant
improvement in functional outcome, and had higher rates of symptomatic ICH in the
treatment group. Meta-analysis of pooled data from six randomized controlled trials of IV
t-PA found decreased odds of an excellent outcome (mRS ≤ 1) as onset-to-treatment times
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increased, but there was still a significant benefit in the 3 to 4.5 hour time window83.
Efficacy of IV t-PA given within 3 to 4.5 hours post onset was confirmed in the European
Cooperative Acute Stroke Study (ECASS) III trial, which found significantly higher rates
of excellent functional outcomes (52 vs 45% in the control group) in the IV t-PA group,
and similar mortality rates despite increased risk symptomatic ICH84. Administration of
IV t-PA remains a frontline therapy for AIS patients, but the time window still presents a
major barrier to treatment; studies suggest up to 67% of patients not receiving thrombolysis
are deemed ineligible because of the time window85.
Current clinical guidelines suggest administering IV t-PA within 4.5 hours of
symptom onset, at a dosage of 0.9 mg/kg, with the first 10% of the dose given as a bolus58,
although a dosage of 0.6 mg/kg may result in similar improvement in functional outcome
with lower rates of symptomatic ICH86. Patients can be treated regardless of age, or
admission stroke severity (assessed by the National Institute of Health Stroke Scale or
NIHSS), provided admission non-contrast CT (NCCT) rules out primary ICH74. IV t-PA
within 4.5 hours is currently indicated for both genders, but the treatment effect may be
more beneficial in women than in men87. Patients who are at risk of a serious bleeding
complication due to recent stroke, head trauma, brain surgery, or administration of low
molecular weight heparin within 24 hours preceding the stroke should not be treated with
thrombolysis58. Blood glucose must be measured before initiating thrombolytic therapy
because hypoglycemia can be incorrectly diagnosed as AIS88, and severe hyperglycemia
(blood glucose > 400mg/dL) is associated with lower recanalization rates89 and increased
the risk of ICH and poor outcome90. Consequently, diabetes mellitus is also associated
with higher rates of hemorrhagic transformation91 and in-hospital mortality92 in AIS
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patients treated with thrombolysis, though studies suggest diabetic AIS patients still benefit
from IV t-PA93. Hypertension is also associated with increased risk of hemorrhagic
transformation following thrombolytic therapy, increased mortality, and decreased
probability of good functional outcome94. Hypertensive patients can only receive IV t-PA
if systolic and diastolic blood pressure can be safely lowered to less than 185, and
110mmHg respectively, and should be maintained at less than 180 and 105mmHg
respectively for twenty-four hours after initiating thrombolytic therapy58.

1.2.2

Mechanical Thrombectomy
Successful trials of IV thrombolysis were a breakthrough in treatment of AIS, but

the time window still posed a major impediment to treatment85, and recanalization rates
were poor for large vessel occlusions (LVO)95. LVO refers to occlusions of large proximal
cerebral arteries, such as the M1 segment of the MCA, anterior cerebral artery (ACA),
distal ICA, or the basilar artery. Although only ~40% of ischemic strokes are caused by
LVO they account for ~60% of post-stroke dependence and ~95% of post-stroke
mortality96. Poor recanalization rates for LVO and the relatively short time window for
administrating IV t-PA were major drivers for development of IAT for AIS.
Early attempts at IAT involved administering thrombolytic drugs directly to the
thrombus by guiding an endovascular microcatheter delivery system to the occlusion site,
allowing a high concentration of thrombolytic agent to be delivered to the thrombus while
also minimizing systemic exposure, theoretically minimizing the risk of hemorrhage. The
earliest clinical use of IAT in the literature used intra-arterial (IA) delivery of streptokinase
to treat patients with basilar artery thrombosis and reported excellent outcomes in 3 of 5
patients97. Later studies found that IA recombinant u-PA within 6 hours of onset was
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associated with improved functional outcome98,99, but also high rates of ICH, and
symptomatic ICH98,99. Several studies also combined IV t-PA initiated as soon as possible,
followed by IA delivery of t-PA directly to the thrombus for patients who still had clot
visible on angiography. These studies found similar rates of ICH and a nonsignificant
improvement in outcome compared to IV t-PA alone100–102. Although IA thrombolysis was
shown to improve recanalization rates compared to IV thrombolysis98–103, there is no level
1 evidence that IA thrombolysis alone improves functional outcome compared to IV
thrombolysis alone.
Catheter devices for mechanically removing thrombus were developed as an
alternative to IA delivery of thrombolytic agents. Mechanical removal of the thrombus is
advantageous because of high recanalization rates for LVO104, faster recanalization relative
to IA thrombolysis which requires prolonged infusion of thrombolytic agents for up to 2
hours102, and reduced hemorrhage risk by avoiding the use of thrombolytic drugs105. In a
mechanical thrombectomy procedure: a microcatheter is advanced to the occlusion site and
passed through the thrombus, the device is deployed distal to the thrombus and retracted to
ensnare the thrombus and pull it to a proximally placed guide catheter for aspiration106.
The first endovascular device approved for AIS treatment used a flexible corkscrew design
and was called the Mechanical Embolus Removal in Cerebral Ischemia (MERCI)
retriever106. Trials of the MERCI device showed that LVOs could be recanalized in 46%
to 57% of patients treated within 8 hours, but design limitations meant up to 6 passes had
to be made to remove the entire clot106,107. Second generation devices using a flexible,
retrievable wire stent were shown to be superior to the MERCI device108,109.
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Early randomized controlled trials of mechanical thrombectomy all failed to show
a significant improvement in functional outcome compared to IV t-PA110–112, but these
trials had several important limitations. Only ~20% of patients in the IAT arm of each trial
were treated with second generation devices110–112, and in 2 trials 50% to 66% of patients
were treated with IA thrombolysis instead of thrombectomy110,111. IV t-PA was not
administered to patients randomized into the IAT arm of 1 trial. As a result, treatment was
initiated an average of 1h later in patients receiving IAT compared to patients treated with
IV t-PA111. CT angiography (CTA) was not used to confirm the presence of a LVO for all
patients in 2 of the trials, resulting in many patients randomized into the IAT arm not
having an occlusion that was suitable for treatment with IAT110,111. Lessons learned from
these trials informed the design of subsequent randomized, controlled trials of IAT.
In 2015, 5 trials comparing patients treated with IV t-PA plus IAT to patients treated
with IV t-PA alone were stopped early after demonstrating significant benefit of IAT. All
5 trials used NCCT or MRI to rule out ICH, angiography to confirm the presence of LVO,
and initiated IAT within 6113–116 to 8117 hours of symptom onset.

In addition to

demonstrating the efficacy of IAT for treating patients with LVO, these trials also provided
early evidence that advanced neuroimaging, such as multi-phase CTA or CTP could be
used to identify patients with a small infarct core and large penumbra, who would be most
likely to benefit from revascularization. The ESCAPE trial, performed in Canada, used a
semi-quantitative scale called the Alberta Stroke Program Early CT Score (ASPECTS) to
assess NCCT for signs of early ischemic damage indicative of a large infarct core118, and
a novel CTA imaging technique (multiphase CTA) to evaluate the degree of collateral
circulation, which reflects the amount of residual CBF in the ischemic tissue119. The
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SWIFT-PRIME and EXTEND-IA trials, performed in the United States and Australia/New
Zealand respectively, used thresholds applied to parameter maps from CTP to estimate the
volume of infarct and penumbra; patients with large infarct volumes and/or small
penumbra volumes were excluded113,115. These trials, which included imaging to evaluate
the extent of irreversibly damaged infarct and salvageable penumbra, had higher rates of
good functional outcome in the IAT group (53% to 71%), than the MRCLEAN and
REVASCAT trials, conducted in the Netherlands and Spain respectively, which did not
use advanced neuroimaging (33% to 44%)116,117.
Several retrospective studies noted that there was no significant difference in the
rate of good functional outcome, symptomatic ICH or mortality when patients were triaged
based on admission CTP or MRI120,121, providing more support for image-based triaging
rather than strictly time-based triaging. The efficacy of image-based triaging for IAT was
confirmed recently in the DEFUSE 3 and DAWN trials – two randomized, controlled trials
comparing standard medical therapy alone to standard medical therapy plus IAT in patients
arriving up to 16 hours122 to 24 hours123 post symptom onset, or those with unknown onset
times. Patients were eligible if they had LVO confirmed on CTA, no evidence of
hemorrhage on NCCT, and mismatch between infarct volume and either penumbra
volume122 or clinical deficit123. The treatment effect of IAT (difference in rate of functional
independence between IAT and control groups) seen in these trials (28% to 36%)122,123 was
paradoxically larger than what was seen in a meta-analysis of the trials where IAT was
initiated within 6 hours of symptom onset (19.5%)104. This was mainly because patients
in the control group were not eligible for IV t-PA since these trials only enrolled patients
where time from symptom onset was 6 hours or more (87% of patients in the control groups
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in earlier trials received IV t-PA)104. Nevertheless, the rate of IAT-treated patients with
good functional outcomes (45% to 49%)122,123 was similar to when IAT was initiated within
6 hours of symptom onset (46%)104, showing that IAT could still be effective in certain
patients up to 24 hours post symptom onset.
Current clinical guidelines recommend performing mechanical thrombectomy with
a stent retriever within 6 hours of symptom onset in patients aged 18 years or older, no sign
of extensive early ischemic damage on NCCT (ASPECTS ≥ 6), and occlusion of the
intracranial portion of the ICA or M1 segment of the MCA confirmed on CTA58.
Mechanical thrombectomy is also recommended up to 24 hours post symptom onset in
patients aged 18 years or older, with CTA-confirmed occlusion of ICA or M1 segment of
the MCA, and either an infarct/penumbra mismatch, defined by the DEFUSE 3 trial
criteria, or a clinical/imaging mismatch, defined by the DAWN trial criteria. Both trials
used thresholds applied to CTP-CBF maps or diffusion-weighted MRI (diffusion-weighted
imaging or DWI) to estimate the volume of infarct core. The DEFUSE 3 trial used
thresholds applied to time-to-maximum (Tmax) maps from CTP or perfusion-weighted MRI
(perfusion-weighted imaging or PWI) to estimate the penumbra volume; patients were
eligible for treatment if penumbra volume was 1.8 times larger than the infarct, infarct
volume was < 70mL, and penumbra volume was > 15mL122. The DAWN trial inferred the
volume of penumbra from clinical assessment with the NIHSS. Clinical deficit defined by
NIHSS reflects the total volume of ischemic tissue since both infarct and penumbral tissue
are functionally silent, therefore a large penumbra volume is implied in patients with severe
clinical deficits but only a small infarct core volume. Patients younger than 80 years were
eligible if infarct volume < 31mL and NIHSS ≥ 10, or if 31mL ≤ infarct volume < 51mL
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and NIHSS ≥ 20; patients 80 years or older were eligible if infarct volume < 21mL and
NIHSS ≥ 10123.

1.3 Medical Imaging in Ischemic Stroke
Medical imaging has become an important part of routine clinical care for AIS.
Structural and functional information from admission neuroimaging is used to inform three
key factors for triaging and management of patients with AIS symptoms: 1) is the stroke
ischemic or hemorrhagic? 2) is there an intravascular occlusion? 3) is there viable
penumbra tissue? NCCT or MRI must be performed at admission to determine if the stroke
is ischemic or hemorrhagic before initiating treatment, since treatment options for AIS can
be detrimental to patients with primary ICH124. CTA or magnetic resonance angiography
(MRA) is also required to define the presence and location of LVO and to assess ease of
access in patients being considered for IAT, and many centers now also routinely use CTP
or PWI to guide treatment decisions. In addition to improving acute diagnosis and
providing personalized triaging based on tissue status instead of time from onset,
physiological information from functional CT, MRI, and positron emission tomography
(PET) has shaped AIS treatment strategies by advanced our understanding of stroke
pathophysiology and tissue viability.

1.3.1

Positron Emission Tomography
PET imaging relies on detection of coincident gamma rays produced in positron

annihilation events to measure the spatial distribution of biological molecules radioactively
labelled with positron emitting nuclides, known as radiotracers. PET is a highly sensitive
imaging modality, capable of detecting nanomolar concentrations of radiotracer, which can
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assess a wide range of hemodynamic, functional, and metabolic parameters depending on
properties of the radiotracer used. A static PET scan performed sometime after radiotracer
administration can measure the spatial distribution of radioactivity in the body relative to
the total injected amount and body weight. On the other hand, dynamic scanning used in
conjunction with arterial blood sampling to quantify arterial delivery (arterial input
function or AIF) of the radiotracer can allow more detailed pharmacokinetic modelling to
be performed125.
PET imaging with 15O-labelled water and oxygen gas allows quantification of CBF,
cerebral metabolic rate of oxygen (CMRO2), and oxygen extraction fraction (OEF)
(fraction of oxygen extracted from the blood). Contemporaneous assessment of blood flow
and oxygen metabolism with PET imaging greatly advanced the understanding of the timedependence of tissue viability in ischemic stroke patients126,127. Tissue with decreased CBF
(CBF < 12 mL∙min-1∙100g-1) and CMRO2 usually progressed to infarction, while
penumbral tissue had CBF between 12-22 mL∙min-1∙100g-1, elevated OEF, and preserved
CMRO2 in the acute phase128. The coupled decrease in CBF and increase in OEF (termed
‘misery perfusion’)129 was representative of still-viable tissue, that would eventually
progress to infarction without reperfusion due to mismatch between metabolic demand and
decreased oxygen delivery from CBF. Animal studies of reversible focal cerebral ischemia
showed that brain tissue with acutely elevated OEF progressed to infarction in animals with
permanent MCA occlusion, but not in animals where the occlusion was reversed after 6
hours, establishing the time-dependence of penumbral viability130,131. Although tissue
compartments in AIS are well defined by CBF, CMRO2, and OEF, there are drawbacks to
using these parameters: a PET scanner and on-site cyclotron are required since the half-life
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of

15

O is only ~2 minutes132, and the rapid arterial blood sampling required for

quantification is invasive.
More recently, tracers labelled with 11C or 18F which bind to neuronal cell surface
receptors have been developed. The half-lives of

11

C and

18

F are ~20 minutes and 110

minutes respectively132, making them easier to use than 15O logistically. One example is
11

C-labelled flumazenil (FMZ), which is a selective, high-affinity ligand for the central

benzodiazepine receptor of the GABA receptor complex133. GABA receptor activity can
be used as a marker of neuronal integrity since GABA receptors are sensitive to ischemic
damage134. Clinical studies have shown that neocortex with decreased uptake of 11C-FMZ
in the acute phase of stroke is infarcted134–136.

Fluoroethylflumazenil (FFMZ), a

fluorinated analog of FMZ, works similarly for mapping GABA receptor activity137, and
can be labelled with 18F, which is advantageous because the half-life is longer than 11C 138.
The density of GABA receptors is low in the basal ganglia and negligible in white matter139,
meaning FMZ, FFMZ and other benzodiazepine receptor ligands are not suitable for
detecting infarction outside of cortical grey matter133. Fluoromisonidazole (FMISO)
radiolabelled with
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F is a hypoxia tracer which has been proposed as a marker of

penumbral tissue. FMISO accumulates in ischemic tissue by binding to macromolecules
after being reduced by nitroreductases140. Studies in a rat MCA occlusion model of AIS
showed a pattern of FMISO uptake throughout the entire MCA territory at early time points
30 to 60 minutes post occlusion, that evolved into a small rim of uptake surrounding the
infarct core, and by 24 to 48 hours post occlusion there was minimal uptake in the final
infarct141,142. A similar time-dependent uptake pattern was also observed in human patients
with AIS due to MCA occlusion143. However, more recent studies using the same rat model
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of AIS found that FMISO was retained in ischemic tissue for up to 6 hours post occlusion,
consequently penumbral tissue which had already progressed to infarction within 6 hours
still had elevated FMISO uptakes144. Subsequent study showed strong FMISO uptake
throughout the MCA territory even when administered up to 6 hours post occlusion, when
most ischemic tissue had likely progressed to infarction. Approximately 50% of the
FMISO-retaining lesion was infarcted on histology, and most of the salvaged tissue in the
lesion had signs of neuronal damage145. These findings suggest increased FMISO uptake
may not be a specific marker of penumbral tissue, further study is required to determine
the applications of this radiotracer in AIS research.
Although the clinical utility of PET in AIS is limited due to cost and logistical
complexity, it is still an invaluable tool for studying pathophysiological processes of AIS
and serves as a gold standard for validating other imaging techniques used in AIS.

1.3.2

Magnetic Resonance Imaging
MRI is a versatile imaging technique used for AIS diagnosis and prognosis, that

can provide both structural and functional information depending on the pulse sequence
used to create the image. Acute ICH can be seen on MRI with gradient recalled echo
(GRE) pulse sequences as a core of heterogenous signal intensity surrounded by a rim of
hypointensity. Studies have shown that NCCT and MRI with GRE pulse sequences are
equivalent for ruling out ICH in patients being considered for IV t-PA124. Thrombus
location and length can also be assessed on susceptibility-weighted imaging (SWI) with
GRE sequences, where the thrombus appears as a hypointense blooming artifact due to
paramagnetic properties of deoxyhemoglobin contained in the clot146. SWI has a high
sensitivity (81% to 86%) and specificity (90%) for detecting clots in the anterior cerebral
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circulation146,147, can reliably measure the length of clots longer than 6mm147, and clot
composition can even be inferred since SWI is related to the red blood cell content of the
clot148.
MRA can be performed either by injecting gadolinium-based contrast agent, or with
non-contrast methods like the time-of-flight (TOF) technique, where flowing blood has
hyperintense signal relative to surrounding static tissue. Both contrast-enhanced and noncontrast enhanced MRA can assess vessel patency in AIS149 and both methods have
advantages and disadvantages. TOF-MRA can be performed when contrast administration
is not possible, but compared to contrast-enhanced MRA, the acquisition time is longer,
making patient motion problematic, and the field of view (FOV) is smaller, so extracranial
arteries cannot be imaged149.
DWI and associated apparent diffusion coefficient (ADC) maps are the clinical gold
standard for detecting early ischemic damage. One of the final steps towards irreversible
tissue damage is cytotoxic edema, where water shifts to the intracellular space due to the
increase in intracellular sodium and calcium after membrane ion pump failure. DWI is
sensitive to Brownian motion of water molecules and detects cytotoxic edema as a
hyperintense lesion due to restricted diffusion of water molecules in the intracellular
space150. Contrast in DWI is due to differences in ADC as well as T2-weighted contrast,
commonly referred to as ‘T2 shine-through’151. To remove the effects of T2 shine-through,
ADC maps are generated where cytotoxic edema is seen as a hypointense lesion with
decreased ADC values151. Acute DWI lesions are highly sensitive and specific markers of
AIS152 and provide reliable estimates of the size and location of the final infarct core
measured on follow-up imaging136,153. Lesion reversal may occur in ~10% of patients,
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where a small part of the acute lesion may appear normal on follow-up imaging,153 however
the reversal is often transient and unlikely to represent salvaged tissue154.
Imaging of the infarct core with DWI can be complemented with PWI performed
using IV administration of exogenous gadolinium-based contrast agent.

PWI with

exogenous contrast agents can be broadly divided into dynamic contrast-enhanced (DCE)MRI, which relies on the T1 effects of gadolinium, or dynamic susceptibility contrast
(DSC)-MRI, which relies on the susceptibility effect of gadolinium. Signal enhancement
versus time curves are measured by T1-weighted or T2/T2*-weighted echo-planar imaging
and summary parameters like time-to-peak (TTP) and area-under curve (AUC) can be
determined in a model-free approach155. Or quantitative maps of CBF, Tmax, and other
parameters can be computed with pharmacokinetic modelling if the measured signal
enhancement curves are converted to contrast concentration versus time curves, and an AIF
is available. Measured signal enhancement is not linearly related to contrast concentration
in PWI, making absolute quantitation of hemodynamic parameters more difficult. Contrast
concentration can be calculated from signal enhancement using pulse sequence-dependent
equations155, DCE-MRI requires pre-contrast T1 mapping in addition to pulse sequencedependent equations to calculate the contrast concentration versus time from the measured
signal156. Accurately measuring the AIF can also be problematic because of in-flow/outflow effects (blood flowing into or out of the imaging volume causing signal increases and
decreases respectively), limited temporal resolution and other factors156. When an AIF of
sufficient quality cannot be derived from the PWI scan, alternatives such as populationaveraged AIFs may be used instead156, but this can lead to errors in parameter calculation
if the chosen population-averaged AIF is not representative of the individual patient.
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Studies have shown that the deconvolution-based Tmax parameter is optimal for
identifying penumbra (Tmax > 6s) on admission DSC-MRI157,158. Model-free summary
parameters do not account for arterial delivery and are therefore affected by factors like
bolus dispersion and cardiac output159, but studies show TTP is highly correlated with Tmax
and performs similarly for predicting penumbra volume160,161.

DWI/PWI mismatch is a

widely used neuroimaging paradigm for managing AIS patients based on infarct and
penumbra volumes measured from admission DWI and PWI using fully automated postprocessing software (RApid processing of PerfusIon and Diffusion, or RAPID)162.
DEFUSE 3 recently used RAPID to show that patients with LVO and mismatch on
admission DWI/PWI or CTP (infarct volume < 70mL, infarct/penumbra ratio > 1.8, and
penumbra volume > 15mL) can still benefit from IAT up to 16 hours post symptom
onset122. PWI can also be performed with endogenous contrast using arterial spin labelling
(ASL), where magnetically-labelled, arterial blood acts as an endogenous tracer rather than
administering exogenous gadolinium-based contrast. However, ASL is not commonly
used for AIS because relaxation of the magnetic label during prolonged transit times caused
by ischemia can lead to poor signal-to-noise ratio and underestimated CBF163.
Another MRI-based paradigm for AIS patient management is mismatch between
admission fluid-attenuated inversion recovery (FLAIR) and DWI. Hyperintense lesions
on FLAIR are highly sensitive markers of infarct core164 but are generally not visible in the
first 3 hours post onset, whereas DWI lesions are visible 1 hour or less post onset 165.
Studies have shown that FLAIR-DWI mismatch (hyperintense DWI lesion with no FLAIR
lesion) is a surrogate marker of ischemia duration166 that can identify patients with time
from symptom onset < 4.5 hours with high specificity167. A recent randomized, placebo-
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controlled trial found that treating patients with FLAIR-DWI mismatch and unknown
stroke onset time with IV t-PA improved functional outcome despite increased risk of
symptomatic ICH168. FLAIR-DWI mismatch could potentially be used in patients with
unknown onset times (approximately 14 to 25% of all AIS patients)169,170 to identify those
with ischemia duration < 4.5 hours, who are more likely to benefit from thrombolysis.
In addition to providing anatomical and functional information about vessel
patency, tissue viability, ischemia duration and other factors, MRI is more readily available
in the AIS setting than PET and does not require ionizing radiation. However, MR scanners
have limited availability compared to CT outside of large city hospitals or academic
centers, and patients with MRI contraindications (e.g. claustrophobia, ferromagnetic
implants, pacemakers) must be excluded from imaging; screening for contraindications
also results in longer door-to-needle times compared to CT171. Despite these limitations,
MRI is an important modality for triaging and management of AIS patients.

1.3.3

Computed Tomography
CT is the most commonly used modality for assessing AIS patients because it is

more widely available172, less expensive, and faster compared to MRI, and CT can be
performed without first screening the patient for common MRI contraindications. Patients
with AIS symptoms are often assessed with NCCT, CTA or multiphase CTA, and CTP.

1.3.3.1

Non-Contrast Computed Tomography

Admission NCCT is required for any patient with stroke symptoms to rule out nonvascular stroke mimics and primary ICH. The intensity in each voxel of CT images,
expressed in Hounsfield Units (HU), is linearly proportional to the x-ray linear attenuation
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coefficient. NCCT has good sensitivity for detecting acute phase ICH which appears as a
hyperintense lesion124, and is more cost-effective as a screening tool than MRI74. In
addition to ruling out ICH, careful examination of NCCT can also yield information about
early ischemic damage and clot characteristics. ASPECTS is a standardized CT reading
method based on assessment of 10 regions of interest (ROI) located in the MCA territory
visible in two 5mm thick CT slices, one at the level of the thalamus and basal ganglia, and
one just rostral to ganglionic structures. One point is subtracted from 10 for each ROI with
evidence of early ischemic damage118. Signs of early ischemic damage visible on NCCT
include hypoattenuation, sulcal effacement due to mass effect from edema, and loss of
gray-white matter differentiation, including loss of the insular ribbon and obscuration of
the lentiform nucleus173. ASPECTS ≤ 7 has been associated with increased risk of poor
functional outcome and symptomatic ICH in patients treated with IV t-PA118.
Retrospective studies of patients in the NINDS and ECASS II trials found no significant
effect of baseline ASPECTS on IV t-PA treatment effect174,175, however ASPECTS ≤ 7
was associated with significantly increased risk of symptomatic ICH in the ECASS II
patients175, and there was a trend toward decreased treatment benefit and increased
mortality in the NINDS patients174. Low ASPECTS was also associated with increased
risk of poor functional outcome, mortality, and symptomatic ICH in patients treated with
IAT176 and was part of the exclusion criteria for three of the seminal trials demonstrating
the efficacy of IAT113,114,117. Current clinical guidelines suggest IAT should only be
performed in patients with ASPECTS ≥ 658, but there is some evidence that patients with
ASPECTS ≤ 5 still benefit from IAT177,178.
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Intraluminal thrombus in the distal ICA, M1, and M2 segments of the MCA can
also be visualized in patients as hyperintensity on NCCT, this has been proposed as a
method of confirming the presence of LVO without performing CTA in patients being
considered for IAT. The hyperdense artery sign can detect LVO (as assessed with gold
standard CTA) with high specificity (95-100%) and moderate sensitivity (30-55%) when
NCCT is reconstructed with standard 5mm thick slices179,180, studies have shown that
sensitivity can be improved to 70-100% by using thinner (0.625-1.5mm) slices180–182.
Thrombus length measured on NCCT also agrees with length measured on CTA within
±1mm when slice thickness is ≤ 2.5mm183. Studies have shown that IV t-PA is less
effective for thrombi longer than 10mm on NCCT184, and that clot length and location are
associated with outcome in IAT-treated patients185.

1.3.3.2

Computed Tomography Angiography

CTA requires IV administration of iodinated contrast agent and rapid scanning after
a short delay to capture peak intravascular enhancement. Iodinated k-edge falls within the
energy range of diagnostic x-rays, causing iodinated contrast agents to produce a
measurable increase in x-ray attenuation (~30HU per 1mg/mL of iodine), and therefore
signal intensity measured on CT. CTA source images can be viewed directly, or as
maximum intensity projections or 3D reconstructions with postprocessing; blood vessels
perfused with contrast agent as the image is acquired will appear hyperdense. Evaluation
of flow dynamics is also possible with 4D-CTA or multiphase CTA, where images are
acquired either continuously (4D-CTA), or at multiple discrete time points (multiphase
CTA) as contrast travels through cerebral vasculature, rather than conventional CTA where
imaging at a single time point is performed. CTA has better spatial resolution (~0.5mm
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isotropic resolution)186 than MRA and is less invasive and faster than digital subtraction
angiography (DSA), the gold standard for cerebral angiography, while also providing near
equivalent evaluation of the presence and location of occlusions187,188.
The presence, and location of occlusions on angiography are important prognostic
factors that have implications for patient triaging and management. Current clinical
guidelines require LVO to be confirmed on angiography before initiating IAT58. Failure
to perform admission CTA was one major limitation of earlier IAT trials, resulting in many
enrolled patients having no evidence of occlusion, or occlusions not accessible by IAT
upon arrival to the angiography suite110,111. All trials showing benefit of IAT to date have
used CTA or MRA to confirm the presence and location of LVO. Presence, length and
location of the clot on CTA is also a predictor of recanalization in IV t-PA treated patients.
The benefit of IV t-PA may be diminished in up to ~25% of AIS patients who have no
visible occlusion on CTA189; in patients with visible occlusions, lower recanalization rates
are observed for proximal occlusions95,190, and clots longer than 15mm191. These and other
clot characteristics evaluated on CTA, such as absence of residual flow through the clot192,
can help identify patients who are more likely to benefit from IAT rather than IV t-PA.
The overall extent of anterior circulation clots can also be assessed on CTA using a semiquantitative scale called the clot burden score. Points are subtracted from 10 for absence
of contrast opacification across the full cross-section of any parts of the intracranial ICA,
proximal, or distal M1 segment of the MCA (2 points each), M2 segments of the MCA,
A1 segment of the ACA, and extracranial ICA (1 point each)193. High clot burden scores
have reasonable sensitivity and specificity (73% and 65% respectively) for predicting good
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functional outcome in patients treated with IV t-PA194 and have been associated with
smaller final infarct volume and improved functional outcome in IAT-treated patients195.
Another important aspect of CTA is evaluation of collateral circulation, which
provides alternative routes for blood to reach tissue when a proximal cerebral artery is
occluded. Cerebral collateral circulation consists of the Circle of Willis, which links the
anterior and posterior circulation, connections between external carotid artery branches and
branches of the ICA, and leptomeningeal collaterals which connect territories of the MCA,
ACA, and posterior cerebral artery196. More extensive collateral circulation implies more
preserved CBF in the affected vascular territory, and therefore slower progression of
ischemic penumbra to infarction. Studies have confirmed that more extensive collateral
circulation observed on angiography were associated with smaller final infarct volumes
and better functional outcomes in AIS patients197,198.

There are numerous semi-

quantitative 3- or 5-point scales for grading collateral circulation on CTA by assessing the
degree of collateral vessel opacification in the affected vascular territory relative to the
contralateral side199–202. The regional leptomeningeal collateral (rLMC) score differs by
scoring the collateral circulation relative to the contralateral side in the predefined regions
used in ASPECTS203. Since conventional CTA represents only a single time point, delayed
collateral vessel opacification can be missed depending on bolus characteristics and the
timing of the scan. Dynamic CTA techniques, such as 4D-CTA or multiphase CTA,
provide time resolved data which is less dependent on scan timing or bolus characteristics.
Collateral scoring on dynamic CTA assesses the extent and prominence of collateral vessel,
as well as the time delay for retrograde contrast filling relative to the contralateral side 204.
Multiple studies have found collateral evaluation on dynamic CTA to better predict
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functional outcome compared to conventional single-phase CTA119,205,206, likely due to less
instances of underestimated collateral score due to delayed enhancement missed on singlephase CTA207. Collateral scores from multiphase CTA were used to select patients for IAT
within 6 hours of symptom onset in the ESCAPE trial114.

1.3.3.3

Computed Tomography Perfusion

In the last decade CTP has become more common upon admission of patients with
AIS symptoms. Similar to perfusion-weighted MRI, CTP involves repeated CT scanning
of the brain as an IV bolus injection of iodinated contrast agent is administered and
transient changes in signal intensity versus time (time-density curves or TDC) are
measured in each tissue voxel as contrast passes through brain vasculature.

Signal

enhancement measured in each voxel by CTP is linearly proportional to the concentration
of iodinated contrast agent in the tissue, so difficulties converting measured signal
enhancement to tissue and arterial contrast concentration versus time curves (Q(t) and Ca(t)
respectively) encountered in perfusion-weighted MRI due to contrast non-linearity are
avoided208. CTP also has faster sampling rates and is not affected by in-flow/out-flow
effects seen in perfusion-weighted MRI, allowing the AIF to be measured from the CTP
acquisition rather than relying on population-averaged AIFs and other alternatives used in
PWI.

1.3.3.3.1

Calculation of Hemodynamic Parameters

Hemodynamic parameters can be calculated using deconvolution or nondeconvolution models.

Generally, non-deconvolution models are faster but rely on

simplifying assumptions about brain hemodynamics which do not always hold true,
whereas deconvolution models are more physiologically appropriate but require advanced
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algorithms that extend computation time208.

The work in this thesis only uses

deconvolution models. The tissue TDC measured in each voxel during the CTP acquisition
is dependent on the arterial TDC (Ca(t)), and the inherent hemodynamic properties of the
tissue208. Under ideal injection conditions, where a unit bolus of contrast is deposited in a
feeding artery immediately upstream from the tissue of interest (i.e. Ca(t) is a delta function
of unit height), Q(t) in each voxel would depend only on the hemodynamic properties of
the tissue. The theoretical Q(t) corresponding to an ‘impulse’ arterial input is called the
impulse residue function (IRF or R(t)) and can be thought of as the fraction of contrast
remaining in the tissue over time following a unit bolus of contrast. Clinical replication of
these injection conditions is not practical, so the AIF is measured from a proximal cerebral
artery and assumed to represent the arterial input to all of the tissue of interest208. Since
the amount of contrast delivered to the tissue at any instant is 𝐹 ∙ 𝐶𝑎 (𝑡), any general Q(t)
can be represented as the sum of time-shifted IRFs scaled by F·Ca(t) at each time point209
(Figure 1.1):
𝑡

𝑄(𝑡) = 𝐹 ∙ ∫ 𝐶𝑎 (𝑡′) ∙ 𝑅(𝑡 − 𝑡 ′ ) ∙ 𝑑𝑡′
0

Where t is the total scan time. The integral term is the convolution of the arterial
TDC and the IRF. This can be rewritten as the following by multiplying F into R(t) (flowscaled IRF or RF(t))210:
𝑄(𝑡) = 𝐹 ∙ 𝐶𝑎 (𝑡) ⊗ 𝑅(𝑡) = 𝐶𝑎 (𝑡) ⊗ 𝑅𝐹 (𝑡)
Where ⊗ is the convolution operator (Figure 1.2).
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Figure 1.1: The concept of deconvolution applied to CT Perfusion

Fig. 1.1: This figure was adapted from ‘Functional CT: Physiological models’, by TingYim Lee published in Trends in Biotechnology (2002; 20(8): 3-10)210. The left and right
columns show arterial TDCs and the corresponding tissue TDCs. The top row illustrates
the concept of time invariance; if hemodynamic conditions are constant over the duration
of the CTP acquisition, then two impulse arterial inputs of equal height occurring at
different times result in two identical IRFs, shifted in time. The middle row illustrates the
concept of linearity; if enhancement measured by the CT scanner is linearly related to the
concentration of contrast agent, then the height of the IRF will be linearly related to the
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arterial enhancement multiplied by the flow (F) delivery. Under these conditions, any
general AIF can be represented as a series of delta functions with heights given by the
measured arterial contrast concentration versus time curve, and any tissue TDC can be
represented as a series of time-shifted IRFs scaled by the measured arterial contrast
concentration versus time curve.
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Figure 1.2: Graphical representation of CTP deconvolution equation

Fig. 1.2: Graphical representation of the operational equation of CTP. Q(t) measured in
each voxel of brain tissue is a combination of the arterial delivery of contrast (represented
by AIF(t)) and the inherent hemodynamics of that voxel of brain tissue (described by
RF(t)), therefore Q(t) is a convolution of the AIF and RF(t).
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Deconvolution algorithms solve for RF(t) in each tissue pixel to approximate the
regional tissue hemodynamics that would be measured under ideal injection conditions by
removing the effect of Ca(t). The shape of RF(t) depends on the model used in the CTP
software, all work contained in this thesis uses a form based on the Johnson-Wilson
model211. The Johnson-Wilson model allows CBF, CBV, MTT, contrast arrival time (T0),
and Tmax (Figure 1.3).
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Figure 1.3: Sample IRF

Fig. 1.3: An example of the flow-scaled IRF from the Johnson and Wilson model. The
delay between contrast arrival at the AIF and the tissue TDC is the arrival time (T0), the
height of the initial box-shaped portion is equal to CBF, and the area under the IRF is equal
to CBV. The width of box (w) is the minimum transit time through the tissue, and E
describes the fraction of contrast with transit time equal to w. The remaining fraction of
contrast (1 – E) with transit times longer than w is described by the tail portion, which is
assumed to be an exponential decay function with rate constant k. MTT is calculated as
CBV divided by CBF, as required by the central volume principle, and Tmax is calculated
as T0 plus half of the MTT (T0 + MTT/2)210.
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1.3.3.3.2

Technical Considerations for CTP Acquisition

Current commercially available CTP software packages are almost fully automated,
the only user input is reviewing the AIF and venous output function (VOF) automatically
selected by the program, or manually selecting them if the software does not have
automated post-processing features. The AIF is usually measured from a large cerebral
artery that is orthogonal to the image plane to minimize partial volume averaging.
Depending on the brain region covered by the scan, the intracranial ICA, or ACA are
commonly used for the AIF, and the VOF is usually taken from the posterior superior
sagittal sinus212. Underestimation of the AIF due to partial volume averaging can be
corrected by normalizing the area under the AIF to that of the VOF210.
CTP was previously restricted by limited z-axis coverage, but modern 256/320-row
multidetector CT scanners can cover 16cm in the z-axis direction, allowing nearly the
whole brain to be imaged in a single scan212. Scan coverage can be increased further using
table-toggling techniques, where the table is moved back and forth so that two adjacent
slabs are imaged during the same bolus injection212. One limitation of CTP is the ionizing
radiation dose to the patient, which depends not only on x-ray tube voltage and current, but
also the duration of the scan, the temporal sampling interval, and other factors. CTP scan
duration varies from 40-60s when only perfusion is necessary, up to 90-180s when both
perfusion and BBB permeability are assessed. Radiation dose increases as sampling
interval shortens, so longer scans are divided into multiple phases with progressively longer
sampling intervals to reduce radiation dose to the patient. Multiphase scans generally
consist of a 30-45s arterial phase with a sampling interval of 1 image per second, then a
30-45s venous phase with a sampling interval of 1 image per 2-3s, and finally a 90-120s
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delayed phase with a sampling interval of 1 image per 15s, to limit radiation dose213. When
table-toggling is used to increase z-axis coverage the sampling interval must be decreased
to 1 image every 2-3s to accommodate table motion. Radiation dose can be decreased by
shortening the scan duration, but if the scan is too short to capture the delayed contrast
washout from ischemic tissue it can lead to errors in quantitative values. Previous studies
have found that shortening the duration of perfusion scans to 40-50s results in
underestimated CBV, MTT and Tmax values in AIS patients, and by extension, under- and
overestimated infarct/penumbra volumes derived by Tmax and CBV thresholds
respectively214–217. Further study is required to determine optimal CTP scan duration for
AIS applications that can minimize the radiation dose to the patient without affecting
quantitative results. Increasing the sampling interval in the first phase of the scan can also
decrease the dose, but can lead to errors in quantitative perfusion results, particularly for
sampling intervals longer than 1 image every 3s. Studies have found quantitative perfusion
results may be over- or underestimated at sampling intervals ≥ 3s

218,219

, but qualitative

lesion appearance, diameter, and volume218,219, and ASPECTS applied to CTP maps are
relatively unaffected219. Tube voltage of 80kVp is recommended for brain CTP since this
results in mean x-ray energy closer to the iodine k-edge, improving iodine detection
sensitivity, while also decreasing radiation dose compared to higher tube voltage
settings220. Tube current of 100-200mA is recommended for brain CTP but decreasing
tube current to 50mA may reduce effective dose by ~50% without significantly affecting
quantitative perfusion values221. Alternative image reconstruction techniques, such as
adaptive statistical iterative reconstruction, can also be used to lower radiation dose without
impacting image quality222, or improve quality of CTP maps without increasing radiation
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dose223. A standard 2-phase CTP study for assessing perfusion and BBB permeability has
an effective dose of ~5mSv224. It is commonly assumed that an effective dose of 1Sv will
increase the risk of dying from cancer by 5%225; extrapolating this to a dose of 5mSv means
that a brain CTP study increases the risk of cancer mortality by ~0.025%.

1.3.3.3.3

Applications for Ischemic Stroke

The main application of CT Perfusion in AIS is estimating the volume of
irreversibly damaged infarct core and/or salvageable penumbra by applying thresholds to
hemodynamic parameter maps. CTP-derived infarct and penumbra volumes may be
underestimated for z-axis coverage ≤ 8 and 4cm respectively, compared to what would be
measured with 16cm coverage226. Nevertheless, even with 4cm coverage, studies have
found infarct volumes quantified on admission CTP were better correlated with final infarct
volume227 and more predictive of functional outcome than ASPECTS assessed on
NCCT228,229 and CTP maps, as well as collateral score and clot burden score assessed on
CTA229. Standardization of thresholds used to define infarct and penumbra has been
problematic.

Studies show infarct volumes derived using different thresholds are

significantly different230, and that even the same threshold applied to maps computed using
different software will produce different infarct volumes because of differences in the
deconvolution algorithm used by each software231. Based on results from DEFUSE 3 and
DAWN, current clinical guidelines recommend CTP with postprocessing by the RAPID
software package to determine eligibility for IAT in AIS patients with LVO and either
unknown symptom duration, or symptom duration between 6-24h58. Patients are selected
for IAT based on mismatch between infarct (CBF ≤ 30% of the contralateral side) and
penumbra (Tmax > 6s) volumes122, or mismatch between infarct volume and severity of
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clinical deficit as assessed by NIHSS123 (both mismatch paradigms are described in detail
in the Mechanical Thrombectomy section above).
Assessing permeability-surface area product (PS) of the blood-brain barrier with
CTP can also be used to predict the risk of hemorrhagic transformation following
revascularization therapy. Both the average PS within the ischemic territory and the
volume of tissue with elevated PS can predict hemorrhagic transformation with good
specificity (83-94%) and moderate sensitivity (51-77%)232,233. In the future PS maps from
CTP could be useful for identifying patients with an increased risk of hemorrhagic
transformation, where use of thrombolytic agents may be contraindicated. CTP performed
after treatment also has the potential to provide additional prognostic information beyond
what is available with angiographical imaging. Approximately ~15% of IAT-treated
patients from clinical trials had near-complete or complete reperfusion on follow-up DSA
(as assessed by the semi-quantitative modified thrombolysis in cerebral infarction scale, or
mTICI scale) but still went on to have poor functional outcomes 113,114,116,117,234.
Reperfusion assessed on follow-up CTP was a better predictor of outcome in AIS patients
treated with IV t-PA than recanalization of the occluded vessel on follow-up CTA235.
Follow-up CTP may also be a better predictor of functional outcome in IAT-treated patients
than applying the mTICI scale to post-procedural DSA. As further advances are made in
neuroprotective drugs and therapies, assessment of reperfusion following treatment of AIS
may become important for identifying patients most likely to benefit from additional
therapy.
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1.4 Animal Models of Ischemic Stroke
Animal models of focal cerebral ischemia have been developed to further our
understanding of stroke pathophysiology and develop treatment strategies and novel
imaging techniques in a controlled environment. Animal models remove the impact of
confounding factors commonly found in the clinical setting (e.g. diabetes, vascular
cognitive impairment, previous stroke, etc.) and provide precise control over variables like
ischemia duration, something that is impossible to control in a clinical setting.
Additionally, radiation dose is less of a concern in animal models than in patients, so
multimodal CT or PET imaging can be performed at several time points with less concern
for the cumulative radiation dose. Although animal models present many advantages over
clinical studies, it should be noted that no animal model completely replicates the complex
processes of ischemic stroke in humans, often making translation of results from animal
studies to the clinical setting challenging.
Most models of focal cerebral ischemia rely on occlusion of the MCA with an intraarterial approach. The intraluminal suture procedure involves advancing a filament of
surgical suture through the ICA to block the MCA; this model can be used to replicate
permanent occlusion or transient occlusion by removing the suture after a predefined
time236. Mechanical abrasion from the filament can result in increased risk of endothelial
damage or hemorrhage, but when implemented properly this procedure creates infarcts that
increase in volume over time and are highly reproducible between animals. Another option
is IA injection of either microspheres or autologous blood clots into the ICA, causing
occlusion of the MCA. Using the embolic model with an autologous blood clot is the only
model suitable for studying thrombolytic agents237, but infarct size is also more variable
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due to variability of endogenous fibrinolysis between animals. Other models require a
craniectomy to expose, and then occlude the MCA using electrocoagulation, clips, or
ligatures238, or by applying the vasoconstrictor endothelin-1 (ET-1) onto the exposed
MCA239. ET-1 can also be injected into the MCA territory to cause vasoconstriction which
eventually leads to infarction240.
Animal stroke studies are most commonly performed in mice and rats because they
are reproducible and cost-effective. However, rat brains are lissencephalic (smooth surface
lacking gyri and sulci), and the proportion of white matter is much lower than in humans,
limiting the applicability of results from these models to humans. Therefore, stroke models
have also been developed in larger animals such as dogs, pigs, and even primates, all of
which have a gyrencephalic brain, and a proportion of gray and white matter more like
humans. The disadvantages of using larger animals are increased cost, ethical concerns,
and differences in cerebrovascular anatomy. Many large mammals used for biomedical
research (e.g. pigs) have a rete mirabile in the extracranial portion of the internal carotid
artery – a fine meshwork of blood vessels which reconstitutes into the internal carotid
artery further downstream in the carotid canal241, making it impossible to employ the
intraluminal suture, and embolic stroke models in these animals. Most large animal stroke
models require craniectomy of the orbital rim242, or enucleation of the eye243 so that the
MCA can be exposed and occluded. These complex surgical procedures make it difficult
to maintain the animal at its basal physiological state throughout the duration of the
experiment. Animal models of stroke are an important way of testing new treatment
techniques for AIS, a less invasive large animal stroke model could improve clinical
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translation by making it easier to test new therapies in models that are more representative
of human stroke.

1.5 Future Diagnosis and Treatment of Stroke
Treatment of AIS, and neuroimaging-based triaging and management of AIS
patients have progressed rapidly in recent decades, but there are still subgroups of patients
where the efficacy of existing treatments have not been confirmed. For example, the
benefit of IAT for treating distal MCA (M2 or M3 segment), ACA, and posterior cerebral
circulation occlusions is not clear. Meta-analyses of pooled data suggested treating distal
occlusions of the MCA (M2 or M3 segments) with mechanical thrombectomy may be
beneficial, but statistical significance was not found104,244,245. Occlusion of the ACA and
the posterior cerebral circulation are responsible for ~5%246 and 15-20%247 of AIS
respectively. There is some evidence that thrombectomy with stent retrievers improves the
likelihood of recanalization and good outcome in patients with ACA occlusion246,248, and
basilar artery occlusion249, but more study is needed to refine thrombectomy techniques
and define appropriate inclusion criteria for treatment. Because of the uncertain benefit of
IAT for treating distal occlusions, these patients are currently treated with IV t-PA, but
treatment with thrombolysis is restricted by the 4.5h time window, and inability to treat
patients with unknown onset times. A recent randomized, placebo-controlled trial showed
that patients with unknown stroke onset times who have FLAIR-DWI mismatch benefit
from IV t-PA168, but equivalent CT-based selection criteria should also be studied due to
the greater availability of CT outside of major cities.
Research into new thrombolytic drugs and neuroprotective techniques is also
ongoing. Alteplase is the only t-PA class drug approved by the FDA but there is some
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evidence that IV administration of tenecteplase (TNK), another recombinant t-PA with
higher fibrin specificity250 and a longer half-life, could result in greater reperfusion rates251
and lower rates of ICH252. TNK may have a role in routine care if the efficacy is shown to
be equivalent to alteplase because it is less expensive and easier to administer (one bolus
versus a bolus followed by 1h infusion of alteplase)252. Trials comparing IV TNK and
alteplase for AIS treatment within 4.5h of onset and treatment of minor stroke or transient
ischemic attack within 12 hours of onset are ongoing.
Neuroprotective drugs and therapies are also being studied as method to maximize
penumbra salvage by slowing the progression of ischemic tissue toward infarction. One
prominent example is the neuroprotective drug NA-1, which acts on the postsynaptic
scaffolding protein PSD-95 to inhibit glutamate excitotoxicity. NA-1 reduced final infarct
volume by ~40% in a non-human primate model of AIS253 and was also found to be safe
and effective for reducing the number of DWI lesions in humans following endovascular
brain aneurysm repair (a procedure where small embolic strokes are common)254. A phase
3 randomized, placebo-controlled trial is currently underway to determine the efficacy of
NA-1 for improving functional outcomes in AIS patients treated with IAT.

Non-

pharmaceutical neuroprotective therapies are also under investigation, including selective
brain cooling with intra-arterial infusion of cold saline255,256. Previous research has shown
that inducing hypothermia provides neuroprotective effects in the acute phase of stroke by
reducing CMRO2 and excitotoxicity, and in the subacute phase by preserving BBB
integrity257. IA infusion of cold saline offers similar neuroprotective effects without the
adverse effects associated with hypothermia, such as pneumonia or cardiac arrhythmia258.
A recent study of cold saline infusion performed before and after IAT resulted in smaller
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final infarct volume and a non-significant trend toward better functional outcomes255. As
neuroprotective drugs and therapies continue to be refined, imaging-based selection criteria
will need to be studied to identify patients who will be most likely to benefit.

1.6 Research Objectives
The main objective of this work was to identify limitations and potential areas for
improvement in current CTP-based methods for guiding AIS treatment and functional
outcome prognostication following AIS. The thesis is divided into the following parts:
1) Developing a large animal AIS model for deriving CTP parameter thresholds for
infarction after 3h of ischemia.
2) Assessing the effect of scan duration on perfusion parameters calculated by CTP
and determining optimal scan durations for infarction thresholds.
3) Determining the association between reperfusion of previously ischemic tissue
after IAT, as assessed by follow-up CTP, with good functional outcome in AIS
patients.
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Chapter 2

2

Absolute Cerebral Blood Flow Infarction Threshold for 3hour Ischemia Time Determined with CT Perfusion and
18
F-FFMZ-PET Imaging in a Porcine Model of Cerebral
Ischemia

2.1 Introduction
Both MRI and CT are highly sensitive for infarct core. Generally, CT is used
preferentially for stroke diagnosis/prognosis because of availability, cost and speed. Along
with NCCT and CTA, CTP is now consistently acquired at many institutes. CTP based
time-dependent thresholds for infarct core have been recently derived using data from
ischemic stroke patients1. These thresholds will have important implications for patient
triaging and will be useful in wake-up and late presenting strokes. Predicting the infarct
core evolution could help identify patients who will benefit most from transfer to tertiary
centers capable of IAT, the new standard of care.
However, many threshold derivation studies used follow-up imaging performed 17 days after symptom onset to define the infarct core2-8, introducing uncertainty caused by
infarct expansion in the time between admission and follow-up imaging. Furthermore,
some of these studies used DWI to define the infarct core5,6,8. DWI lesion reversal has
been observed in both human and animal ischemic stroke9,10, though it should be noted that
clinical instances of DWI lesion reversal are rare11 and should not deter anyone from using
MRI if it is logistically feasible to acquire in the acute setting.
One alternative, which may circumvent uncertainties caused by infarct expansion
and DWI, is to use large animal stroke models to derive time-dependent thresholds for
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infarction. The logistical complexity of producing and using radiotracers in the clinical
acute stroke setting are not a factor, and radiation dose is less of a concern in animal
models, so the infarct can be defined using PET imaging with radiolabeled FMZ, or its
fluorinated analog, FFMZ. This gold standard method reliably predicts the final infarct
and is less prone to false positives than DWI12. Furthermore, animal models provide
greater control over the time interval between symptom onset and tissue status
determination, allowing infarction thresholds to be determined for many different ischemia
durations.
Porcine models are more useful then small animal models since the gyrencephalic
brain is more similar to a human brain in terms of grey/white matter composition and size13.
However, the rete mirabile makes it impossible to use intra-arterial catheter-based methods
commonly used to initiate cerebral ischemia in small animal models14. As a result, most
porcine models of stroke rely on complex and invasive surgical procedures to access the
middle cerebral artery, so a clip or ligature can be applied15,16. Using ET-1 to cause
transient cerebral ischemia does not require complicated surgical procedures and has been
well established in rodents and lower primates17,18. ET-1 binds to endothelin receptors type
A and B in cerebral vascular smooth muscle cells, triggering a potent vasoconstriction that
induces changes in CBF severe enough to induce infarction, with minimal tissue edema19.
Recently, the ET-1 method was used in a porcine model of cerebral ischemia20.
In this study, we presented an ET-1 based porcine model of cerebral ischemia for
determining time dependent CBF thresholds for infarction using CTP and 18F-FFMZ-PET
imaging, and we determined a CBF threshold for infarction after 3hrs of ischemia.
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2.2 Methods
2.2.1

Acute Cerebral Ischemia Model
All animal experiments were conducted following the guidelines of the Canadian

Council on Animal Care and approved by the Animal Use Subcommittee at the University
of Western Ontario (Protocol #2007-050). Duroc Cross Pigs were picked up from a nearby
farm on the day of the experiment and were not housed at the laboratory prior to
experiments. Out of the 11 animals (average weight 26 ± 5 kg) used in this study, 7 were
female and 4 were male. Anesthesia was induced in the animals using 4-5% isoflurane.
Anesthesia was maintained by mask with 3-4% isoflurane until intubation. Propofol (1622 mg/kg) was given IV for intubation. The pig was ventilated (10-15 cc/stroke volume,
20-30 breath per minute) with 2.5-3.5% isoflurane with oxygen and medical air (2:1
medical air to oxygen ratio) for the duration of the experiment. A 22G cephalic vein
catheter was placed for injection of CT contrast (Isovue 370) and 18F-FFMZ. One femoral
artery was cannulated with a catheter for measuring blood pressure, blood gases (pO2 and
pCO2), glucose and pH throughout the experiment. In addition, heart rate, arterial oxygen
saturation, end-tidal carbon dioxide tension (CO2), respiration rate and blood pressure were
continuously monitored (Surgivet). The animal was wrapped in a circulating hot water
blanket and rectal temp were monitored continuously throughout the experiment.
A CT scan was done to identify sixteen contiguous 2.5mm thick slices which
included the largest coronal sections of the brain, then a baseline CTP study was performed
using the procedures outlined in the next section. A target slice location showing the
maximal extent of the MCA territory was selected following the baseline CTP scan. This
target slice was marked on the pig’s head using the CT scanner laser positioning light, the
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scalp was incised (silver nitrate sticks used to control bleeding) and a 1-2mm diameter burr
hole was made with a Dremel hand tool through the skull. A 27G 1 ¼” long needle attached
to a 1mL saline syringe with PE 40 tubing was preloaded with ET-1 and inserted through
the burr hole into the brain. An axial CT scan was then acquired to verify that the needle
tip is within the cerebral cortex in the target slice. 33µg of ET-1 in 150µL of sterile water
was injected at 50 µL/min using an infusion pump. CT Perfusion studies were performed
10 and 30min after the ET-1 injection, and then every 30min for the remainder of the 3hr
monitoring period.
Animals were under anesthetic for the entire study to reduce unnecessary animal
suffering. If anything seriously detrimental had happened during surgery or scanning, the
animal would have been euthanized immediately by intravenous potassium chloride
overdose under full deep anesthetic, however there were no serious incidents so early
termination of experiments was not necessary. At the conclusion of the experiment animals
were euthanized by intravenous potassium chloride overdose under full deep isoflurane
anesthetic.

2.2.2

On-line CBF Monitoring with CT Perfusion
CTP studies were acquired on the GE Healthcare Discovery VCT PET/CT scanner

using the following protocol: 80kV, 200mA, 16 slices of 2.5mm thickness, 1 scan per
second for 60s with a 5s delay from the start of contrast injection (370mg Iodine/mL) at a
dosage of 1mL/kg body weight and at an injection rate of 3mL/s. CTP studies were
completed at baseline, 10 and 30min post ET-1 injection and then every 30min until 3hr
post ischemia. Quantitative CBF maps from each acquired CTP study, calculated within
5min of acquisition, were used to evaluate the perfusion in the ET-1 injection territory. If
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reperfusion caused CBF to rise above the target range of ~20 mL∙min-1∙100g-1 (infarction
threshold with permanent occlusion21), a second dose of ET-1 was injected and perfusion
was checked 10min after, before perfusion monitoring went back to half-hourly intervals.
Physiological parameters that have an impact on CBF were monitored throughout the
experiment.
18

2.2.3

F-FFMZ-PET Imaging for Detecting Cerebral Infarction

FMZ is a selective, high-affinity ligand for the central benzodiazepine receptor of
the GABA-A receptor complex22. Since cortical neurons have a high concentration of
GABA-A receptors, and they are sensitive to early ischemic damage, their activity within
the brain is an indicator of neuronal integrity23. Previous studies in humans and animals
have shown that irreversibly damaged cortical tissue can be detected by decreased binding
of carbon-11 (11C) labeled FMZ22,23. FFMZ is a fluorinated analogue of flumazenil with
similar pharmacokinetics.

FFMZ can be labelled with fluorine-18 (18F), which is

advantageous because of the longer half-life24. Previous studies have shown that PET
imaging with

18

F-FFMZ can be used to map the activity of GABA-A receptors in the

human brain in the same way as 11C-FMZ 25.
18

F-FFMZ-PET imaging was performed on the GE Healthcare Discovery VCT

PET/CT scanner in the 3D acquisition mode. 370MBq of the tracer was injected 25min
before the start of the PET imaging (160min after first ET-1 injection). A CT scan was
acquired for attenuation correction. For the PET imaging, 5 frames of 300s duration each
(25min total time) were acquired on forty-seven 3.3mm thick slices. The 5 frames were
averaged together at all slice locations.
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2.2.4

Data Analysis
For consistency, all CTP functional maps were calculated by one author using

delay-insensitive deconvolution software (CT Perfusion 5 GE Healthcare, Waukesha, WI)
as described previously26. For each pig, CBF maps from each CTP imaging time point
were co-registered, and the median value of each pixel was found using Matlab, to generate
a median CBF map. The median CBF map was then co-registered with the PET images,
average images (perfusion-weighted maps) from the baseline CTP study, and blood volume
(BV) maps at 10min after the first ET-1 injection. All image registration was manually
performed with rigid 3D registration in Analyze 11 (Mayo Clinic, Biomedical
Engineering). The average image was used to draw regions of interest (ROIs) covering the
cortex on the affected and contralateral sides on all slices containing a defect in 18F-FFMZ
uptake. These ROIs were then superimposed onto all other co-registered images. Infarct
pixels were identified on PET images as having signal less than the average minus 2
standard deviations from the contralateral ROI. Since GABA-A receptors are located
primarily in the grey matter27, the average image was used to segment out white matter by
removing any pixels where the CT number was less than 40 HU. To avoid the influence
of large blood vessels on parenchymal perfusion, the BV map was used to exclude blood
vessel pixels if they had a BV greater than the average plus 2 standard deviations from the
affected side ROI. Additionally, pixels with median CBF greater than 100 mL∙min-1∙100g1

were also considered to be blood vessels and excluded from analysis. The remaining

infarct and non-infarct grey matter ROIs were then superimposed onto the median CBF
map and pixel values were imported into an in-house Matlab program for logistic
regression and ROC analysis (Figure 2.1). This process was repeated for each animal that
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had a defect in

18

F-FFMZ uptake. The CBF values that corresponded to the optimal

operating point of the ROC curve (the point closest to the top left corner)28 for each animal
were averaged together to determine the CBF threshold for infarction after 3h of ischemia.
All analysis of images and data was performed by one author (EAW).
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Figure 2.1: Image analysis method

Fig. 2.1 Infarct (pink) was identified on a PET image (top left) acquired 160-185min after
ET-1 injection as pixels in the affected side ROI with signal below the infarction threshold
derived from the contralateral ROI. Pixels with signal above this threshold were classified
as non-infarct (yellow). The average image (top right) was used to segment out white
matter. Blood vessels were identified on the BV map (bottom left) using a threshold
derived from the affected side ROI (see text). Grey matter, vessel-less infarct and noninfarct ROIs were then superimposed onto the median CBF map (bottom right).
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2.3 Results
6 out of 11 animals had irreversible tissue damage (i.e. uptake defect upon

18

F-

FFMZ imaging) and were included in the analysis. After removing vessel pixels, the
volumes of grey matter infarct determined by the PET threshold for these animals were
2.96, 0.74, 2.30, 0.96, 0.97, and 0.80mL, giving an average grey matter infarct volume of
1.46 ± 0.38mL. 3 of the 6 animals that developed infarction required a second ET-1
injection to maintain depressed CBF in the ischemic territory.
The average relative CBF (rCBF normalized to contralateral grey matter) in the
grey matter infarct region was calculated at each CTP imaging time point, for each animal.
The average relative CBF value in the infarct regions over all animals and CTP imaging
time points was 42 ± 16%. Figure 2.2 shows the average rCBF in the infarct region over
time. On average, 60min after the 1st ET-1 injection rCBF dropped to ~40% and remained
there for the duration of the experiment.
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Figure 2.2: Average relative CBF of infarct ROIs

Fig. 2.2: Average relative CBF value from the infarct regions of the 6 animals at each time
point. Error bars indicate standard error.
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The infarct CBF histograms for each animal were normalized by scaling the number
of infarct pixels in each bin up by the ratio of the total penumbra/oligemia pixels to the
total infarct pixels (this scaling operation equalized the number of pixels in the infarct and
penumbra/oligemia histograms). This normalization did not affect the ROC analysis
because the relative frequencies of the CBF values were not changed, but it was necessary
to prevent bias in the logistic regression caused by having a much greater number of pixels
in the penumbra/oligemia group than in the infarct group. CBF histograms for each animal,
and 18F-FFMZ-PET and CBF maps from the slice with the largest extent of infarct for each
animal can be found in Appendix A. Matlab was used to perform a binary logistic
regression on the normalized histogram data for each animal. The probability of infarction
predicted by logistic regression is plotted against CBF for each animal in Figure 2.3. The
average of the 6 CBF values that corresponded to a 75% predicted probability of infarction
in each animal was 4.5 ± 2.6 mL∙min-1∙100g-1.
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Figure 2.3: Predicted probability of infarction versus CBF

Fig. 2.3: Predicted probability of infarction from logistic regression plotted against CBF
for each animal. The average of the CBF values that corresponded to a 75% predicted
probability of infarction was approximately 4.5 ± 2.6 mL∙min-1∙100g-1.
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Figure 2.4 shows the ROC curve for each animal. The average of the CBF values
corresponding to the optimal operating points of the ROC curves28 was 12.6 ± 2.8 mL∙min1

∙100g-1. The sensitivity, specificity, and accuracy for infarct detection corresponding to

the threshold in each animal, and the area under curve (AUC) can be found in Table 2.1.
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Figure 2.4: ROC curves for each animal

Fig. 2.4: ROC curves plotted for each of the 6 animals. Table 1 lists the CBF threshold
derived from the optimal operating point of the ROC curve for each animal, and the
corresponding sensitivity, specificity, accuracy, and AUC.
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Table 2.1: ROC parameters for each animal
Animal Threshold

Sensitivity Specificity Accuracy

AUC

(mL∙min-1∙100g-1)
1

10.1

0.80

0.74

0.77

0.8333

2

8.9

0.80

0.86

0.83

0.8908

3

15.0

0.74

0.70

0.72

0.7650

4

13.2

0.68

0.72

0.70

0.7528

5

12.1

0.75

0.69

0.72

0.7750

6

16.2

0.71

0.75

0.73

0.8110

The relevant parameters from the ROC analysis for each animal. The CBF threshold for
infarction was the CBF value that corresponded to the optimal operating point of the ROC
curve. AUC stands for area-under-curve.
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2.4 Discussion
This study used a porcine model of ET-1 induced cerebral ischemia to determine a
CTP-derived CBF threshold for infarction as determined by 18F-FFMZ-PET imaging after
3 hours of ischemia. A threshold of 12.6 mL∙min-1∙100g-1 was determined using ROC
analysis. Previous animal studies have shown that the threshold for infarction is time
dependent, dropping from 17-24 mL∙min-1∙100g-1 for permanent occlusion to 12 mL∙min1

∙100g-1 for occlusion lasting only 3 hours21,29.
CTP-based time dependent thresholds for infarct core could be important for

identifying late presenting or wake-up ischemic stroke patients that may still benefit from
therapy1. Furthermore, time-dependent thresholds for infarction could be used to predict
infarct growth in the time between admission imaging and reperfusion. This knowledge
would be useful when deciding whether it is worthwhile to transfer a patient from a regional
hospital to an IAT capable tertiary care hospital.
Prior perfusion threshold derivation studies could be affected by methodological
problems. Many studies measure CBF during the acute phase of stroke, but do not
determine the tissue outcome until several days or even weeks later3-5 introducing the
uncertainty of infarct expansion in the interim. Furthermore, some studies use sub-optimal
imaging data sets where the degree of reperfusion is not known4. With the experimental
procedure used in this study CBF measurements and tissue outcome can be determined
contemporaneously, eliminating the error caused by infarct expansion. This model also
allows consistent monitoring of CBF using CTP, which gives information about the extent
of reperfusion in the ischemic tissue.
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The experimental model used in this study has several advantages over other animal
models. The model used by Jones et al involved surgery to expose the MCA, so it could be
occluded using a ligature29. This is an example of a broader category of models which
induce ischemia by occluding the MCA, generally using either an intra-arterial catheter30
or by exposing the MCA and applying a clip or ligature29. Implementing these models of
acute ischemia in pigs can be problematic for several reasons; the rete mirabile makes it
impossible to use an intra-arterial catheter14, and using a clip or ligature requires very
invasive surgical procedures such as an osteotomy on the orbital rim15 or removal of an
eye16. The ET-1 insult used in this study circumvents these difficulties since the only
surgeries required are an incision on the scalp and a small burr hole in the skull (~2mm
diameter). The less traumatic approach increases the ability to maintain the animal at its
basal physiological state throughout the experiment. This is supported by the fact that in
the Jones study 13 of the 33 monkeys had to be excluded from the data analysis because of
subarachnoid hemorrhage, problems with the ligature or other technical issues29 whereas
in this study none of the 11 animals experienced these problems.
In animals 1, 2, and 6 the first dose, administered at the start of the experiment, was
able to maintain rCBF in the final infarct region below 50% for most of the experiment.
However, in animals 3, 4, and 5 the effect of the first dose was transient and a second dose
was required. The second dose was given 90min after the first dose in animal 4 and 30min
after the first dose in animal 5, the average rCBF for the remainder of the experiments
dropped to ~37% and ~32% respectively in the final infarct regions. In animal 3, the
second dose was given 90min into the experiment, causing a transient decrease in rCBF to
43% before it rose above 50% again 150min into the experiment. In this animal the second
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dose may have been given too late to counteract the reactive hyperemia associated with
reperfusion31,32. There was some variation in response to ET-1 injections, but variation in
CBF reduction is to be expected in animal models of stroke. In the study by Jones et al
where cerebral ischemia was initiated in monkeys by ligating the MCA, the average CBF
after ligation in the insular cortex was 17 ± 16 mL∙min-1∙100g-1 29, in this study the average
CBF across all animals and time points after the first ET-1 injection was 15 ± 5 mL∙min1

∙100g-1. On average, rCBF in the final infarct tissue dropped to 56% for the first 30min

of the experiment, from the 1hr time point until the end of the experiment rCBF was
maintained at ~40%. Although the cerebral ischemia caused by ET-1 injections does not
always replicate clinical cases of stroke, the model is still suitable for this study, where the
objective is to cause a reduction in CBF leading to infarction, then determine a CBF
threshold for distinguishing salvaged tissue from tissue which progressed to infarction.
Reperfusion and subsequent reactive hyperemia of the ischemic tissue after the first
ET-1 injection is problematic in this model for several reasons. Premature reperfusion
prevents ischemic tissue from progressing to infarction, this was the main reason that 5 of
11 animals did not develop irreversible tissue damage. When reperfusion occurs midway
through the experiment it can be difficult to accurately define the ischemia duration.
Lastly, some tissue progresses to infarction despite having a relatively high CBF at many
time points during the experiment, either due to a weak response to the first injection or
premature reperfusion and associated reactive hyperemia after the first injection wears off.
This can result in high median CBF in the infarct regions leading to overestimation of the
infarction threshold. For example, the average rCBF in the final infarct region for animal
6 was below 30% between the 30min and 120min time points and above 40% in the final
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three time points. It is possible that infarction was due to CBF dropping to an average
value of 9.4 mL∙min-1∙100g-1 for 30-90min in the middle of the experiment, and the higher
CBF at the other time points resulted in an overestimated threshold of 16.2 mL∙min-1∙100g1

being derived. Using the median CBF value rather than the average CBF lessens the

effect that reperfusion has on the derivation of a threshold.
In our experiments, reperfusion was partially mitigated by using semi-continuous
CBF monitoring with CTP at 30min intervals to identify when reperfusion had started, so
that another dose of ET-1 could be given. At each CTP imaging time point the CBF maps
were calculated on a work station in the CT scanner suite within ~5-8min of completing
the scanning, to monitor for reperfusion from the ET-1 effects wearing off. This method
effectively limited reperfusion of the ischemic tissue, as the average rCBF in the final
infarct region was below 50% for the duration of the experiment in 5 of 6 animals, and the
average infarct rCBF across all animals and time points was 42 ± 16%.

2.5 Conclusion
The objective of this study was to determine a CBF threshold for infarction after 3
hours of ischemia. ROC analysis was used to find a threshold of 12.6 mL∙min-1∙100g-1,
which agrees well with the value of 12 mL∙min-1∙100g-1 determined by Jones et al in 198129.
The ET-1 model of acute stroke used in this study is easier to implement then other large
animal stroke models. Despite some variation in response to ET-1 injections and instances
of premature reperfusion, the model is comparable to other animal stroke models for the
study objective.
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Chapter 3

3

Impact of Truncation Artifacts on CT Perfusion-derived
CBV, CBF, and Time-to-Maximum Measurements in
Ischemic Stroke Patients

3.1 Introduction
CTP has become common in AIS as a tool for quantifying the extent of irreversibly
damaged infarct core and salvageable penumbra1,2. CT is advantageous in AIS since it is
more accessible than MRI3 and can be performed without screening patients for metal
implants and other MRI contraindications, thereby reducing door-to-needle times4.
Applying thresholds to CTP-parameter maps can provide estimates of infarct core volume
which are comparable to infarct volumes from DWI and follow-up CT5-7. These infarct
core volumes from thresholded CTP maps have been used to determine eligibility for
endovascular therapy1,2,8,9 or predicting outcome after endovascular therapy.
However, there is still a lack of consensus about the optimal scan duration for
ischemic stroke applications. Scan durations vary from 40s to 120s from center-to-center10,
despite recommendations to use a 90s-acquisition time11. Shorter scan durations are
desirable due to the decreased radiation dose to the patient, but shortened scan durations
can also lead to truncation of time-density curves from ischemic tissue if the scan duration
is not long enough to capture the complete wash-in and wash-out of the contrast agent. In
AIS patients, since the contrast agent must travel through stenotic arteries or collateral
circulation, the arrival time at ischemic tissue can be longer than 35s 12. Furthermore, once
contrast reaches the ischemic tissue, decreased perfusion pressure can cause the washout
to take 10-20s longer than in normal tissue13. The delayed wash-in and washout of contrast
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agent in ischemic tissue could result in truncated ischemic tissue time-density curves in 44
to 67% of cases10,14, particularly for scan durations shorter than 60s (Figure 3.1).
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Figure 3.1: Truncation of ischemic tissue TDCs

Fig 3.1: Illustration of contrast washout from ischemic tissue being missed when short
(e.g. 40 seconds, red line) scan durations are used for brain CTP in stroke patients.
Deconvolution of truncated TDCs can lead to errors in calculation of hemodynamic
parameters, and by extension, over- or underestimated infarct volumes when thresholds
are applied to parameter maps.
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Previous studies showed that truncation artifacts can result in underestimated CTP
parameters12,15-17, and therefore, under/over-estimated infarct volumes derived by applying
thresholds9,12,15,17,18.
In a previous publication, CTP infarction thresholds for different times from
admission to reperfusion were derived using commercially available perfusion software
(CTP4D, GE Healthcare, Waukesha, WI)5. The effects of truncation on perfusion
parameters and the optimal scan duration18 to avoid such effects could be dependent on
the details of the deconvolution algorithm used to analyze the acquired data. To
investigate the impact of truncation on CTP parameters calculated by this software and
clarify the optimal scan duration to be used with these previously derived thresholds,
CTP parameter maps were computed in AIS patients for five scan durations ranging from
40-150s, using the same software and processing procedures as in the previous
publication5. Median values in ischemic and unaffected tissue were found for each scan
duration, and the shortest scan duration that provided volume estimates within ±2mL of
the volume from the 150s scan duration was determined for two CBF thresholds.

3.2 Methods
3.2.1

Patients
Inclusion criteria were as follows: a) ischemic stroke symptoms, b) age > 18 years,

c) baseline imaging including CTP performed within 12 hours of symptom onset, and
before initiation of therapy, and d) follow-up MRI or CT performed at 24 hours to delineate
infarct extent. Exclusion criteria were as follows: a) intracranial hemorrhage at baseline
CT, b) previous stroke in ipsilateral hemisphere, c) participation in investigational drug or

114

therapy trial, d) motion in admission CTP not amenable to correction. Retrospective
review of consecutive patients from the PRove-IT database (NCT02184936) identified 65
patients meeting the inclusion and exclusion criteria for the study. The local ethics board
approved this retrospective data review study.

3.2.2

Image Acquisition
CT imaging was performed on a 64-slice CT scanner (Lightspeed; General Electric

Healthcare, Waukesha, WI). 45mL of contrast material (68% ioversol, Optiray 320;
Mallinckrodt Pharmaceuticals, St Louis, Mo) was injected at 4.5mL/s followed by a 40mL
saline chaser at 6mL/s. Axial shuttle mode was used to cover an 8cm section of the brain
with a 5mm slice thickness. A two-phase scanning protocol was used where scanning
started 5s after contrast injection5, in the first phase images were acquired every 2.8s for
60s, and in the second phase images were acquired every 15s for 90s. Other acquisition
parameters were 80kV, 350mA, standard reconstruction filter, and 23cm display field of
view. NCCT or DWI was acquired for final infarct delineation in all patients between 24
and 48h post symptom onset5.

3.2.3

CTP Postprocessing
CBV, CBF, and Tmax maps were computed using a commercially available delay-

insensitive software package (CTP4D, GE Healthcare, Waukesha, WI). The AIF was
obtained from a 2x2 voxel ROI in the basilar artery and corrected for partial volume
averaging using the VOF, obtained from an ROI in the posterior superior sagittal sinus. In
cases where the AIF could not be obtained from the basilar artery it was selected from the
contralateral anterior or middle cerebral artery. In-plane patient motion was corrected
using automated software (CTP4D, GE Healthcare, Waukesha, WI). Maps of CBF
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(mL∙min-1∙100g-1), cerebral blood volume (CBV) (mL/100g), and Tmax (seconds) were
calculated by deconvolving the partial volume corrected AIF from the tissue time-density
curves (TDCs). Dynamic CTP images over the first pass of contrast were averaged to
create average maps, which were used as source images for co-registration with follow-up
NCCT or DWI. Shorter scan durations were simulated by sequentially deleting frames
from the end of the CTP acquisitions to create 40, 60, 90, and 120s versions of each 150s
CTP study. For each patient, CBV, CBF, and Tmax maps were computed for all scan
durations. ROIs used to define the arterial input function and venous output function were
saved, so that the arterial input function, venous output function, and all other postprocessing variables could be kept the same for computing maps from all scan durations.

3.2.4

Image Analysis
Follow-up CT or MR images were co-registered with average images from the

admission CTP, details of the registration were published elsewhere19. ROIs drawn using
the follow-up CT/MR images to delineate the infarct, ipsilateral non-infarct (tissue in
ipsilateral hemisphere outside infarct ROI), and contralateral tissue5, were superimposed
onto CBV, CBF, and Tmax maps from all scan durations. Median CBV, CBF, and Tmax
values from each ROI were found for all scan durations.
For CBF maps from all scan durations for each patient, one infarction threshold for
onset to reperfusion time <4.5h (CBF<7 mL∙min-1∙100g-1) and one infarction threshold for
onset to reperfusion time >4.5-6h (7<CBF<13 mL∙min-1∙100g-1)5 were applied to each
5mm slice, and the total infarct volume quantified by each threshold was calculated.
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3.2.5

Statistical Analysis
Statistical analysis was performed in SPSS (IBM SPSS Statistics for Windows,

version 20.0, IBM Corporation, Armonk, NY), p<0.05 was considered significant. Oneway repeated measures ANOVA was used to assess the effect of scan duration on median
CBV, CBF, and Tmax values in the infarct, ipsilateral non-infarct, and contralateral ROIs.
Mauchly’s test was used to test the assumption of sphericity for all one-way repeated
measures ANOVAs20. In case of non-sphericity, the degrees of freedom were adjusted
using the Greenhouse and Geisser method21 to reduce the risk of type I error. Adjusted
degrees of freedom were reported in brackets with the F-statistic for all one-way repeated
measures ANOVA. If the effect of scan duration was significant, then pairwise paired ttests with the Bonferroni correction for multiple comparisons were performed22.
Infarct volumes derived by previously mentioned CBF thresholds from the 120, 90,
60, and 40s scans were tested for statistical equivalence with their corresponding volumes
from the 150s scan using two one-sided t-test (TOST). In TOST, volumes measured from
two different scan durations are equivalent if their difference () is significantly lower than
a predetermined upper equivalence bound (Δu), and significantly higher than a
predetermined lower equivalence bound (Δl)23-25. For this study Δl and Δu were defined as
±2mL, since this corresponded to 10% of the smallest infarct volume threshold used to
determine eligibility for endovascular therapy in the DAWN trial (20mL) 1. The optimal
scan duration for each threshold was defined as the shortest scan duration where the infarct
volume was statistically equivalent, within ±2mL, to the infarct volume from the 150s scan
in a TOST procedure. Additionally, the number of patients where infarct volume derived
by each threshold fluctuated by more than ±2mL relative to that patient’s corresponding
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infarct volume from the 150s scan was reported for all shortened scan durations. Median
CBV, CBF, and Tmax values were reported as the average ± standard error, and average
differences in threshold-derived volume between scan durations were reported with their
95% CIs unless indicated otherwise. Error bars on all figures indicate standard error unless
stated otherwise in the figure caption.

3.3 Results
3.3.1

Patients
65 patients were included in the study, 46% were male and 54% were female. The

average age was 70.0 ± 12.4 (standard deviation) years. 8 patients without infarct on
follow-up images were not included in the infarct region analysis, while all patients were
included in the ipsilateral non-infarct and contralateral region analysis and TOST of
threshold-derived volumes.

3.3.2

Median Parameter Values

3.3.2.1

CBV

Scan duration had a significant effect on median CBV in the infarct ROI (F[2,99] =
120.1, p<0.001), ipsilateral non-infarct ROI (F[3,174] = 85.0, p<0.001), and contralateral
ROI (F[3,159] = 118.2, p<0.001). Panel A of Figure 3.2 shows the average median CBV
value in the three ROIs for each scan duration, post-hoc paired samples t-tests with the
Bonferroni correction showed that for all three ROIs, median CBV was different for all
pairwise scan duration comparisons (p<0.01).
Truncation had the greatest effect in the infarct ROI, where decreasing the scan
duration to 120, 90, 60, and 40s underestimated median CBV by 0.2 ± 0.04, 0.7 ± 0.1, 1.1
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± 0.1, and 1.6 ± 0.1 mL/100g respectively, relative to that from the 150s scan duration. In
the ipsilateral non-infarct and contralateral ROIs decreasing the scan duration from 150 to
40s underestimated median CBV by 1.3 ± 0.1 and 1.2 ± 0.1 mL/100g respectively.

3.3.2.2

CBF

The effect of scan duration on median CBF was not significant for the infarct
(F[3,155] = 2.3, p = 0.086), ipsilateral non-infarct (F[3,185] = 2.4, p = 0.075) or contralateral
(F[3,197] = 0.742, p = 0.531) ROI. Median CBF for each of the three ROIs is plotted against
scan duration in Panel B of Figure 3.2.

3.3.2.3

Tmax

Median Tmax was significantly affected by scan duration in the infarct (F[1,80] =
108.0, p<0.001), ipsilateral non-infarct (F[2,110] = 156.1, p<0.001), and contralateral (F[2,150]
= 116.5, p<0.001) ROI. Median Tmax from each ROI is plotted against scan duration in
Panel C of Figure 3.2. Post-hoc paired t-tests with the Bonferroni correction showed that
for all three ROIs, all pairwise comparisons of median Tmax from different scan duration
were significantly different (p<0.001).
For the infarct ROI, decreasing the scan duration from 150s to 120, 90, 60, and 40s
underestimated median Tmax value by 1.1 ± 0.2, 3.2 ± 0.4, 6.4 ± 0.6, and 9.8 ± 0.9s relative
to that from the 150s scan duration. For the ipsilateral non-infarct and contralateral ROI,
decreasing the scan duration from 150 to 40s underestimated median Tmax by 2.5 ± 0.2 and
1.5 ± 0.1s respectively, relative to that from 150s scan duration.
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Figure 3.2: Median CBV, CBF, and Tmax versus scan duration in infarct, ipsilateral
non-infarct, and contralateral ROIs

Fig. 3.2: CBV (A), CBF (B), and time-to-maximum (Tmax) (C) in infarct (dashed),
ipsilateral non-infarct (dotted), and contralateral (solid) ROIs at each scan duration. Scan
duration had a significant effect on median CBV and Tmax in all three ROIs (p<0.001) but
the effect on median CBF was not significant for any of the ROIs (p>0.05). Error bars
represent standard error.
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3.3.3

Threshold-derived Infarct Volumes
The volume of infarct core for onset to reperfusion time <4.5h identified by the

CBF<7 mL∙min-1∙100g-1 threshold was equivalent to the volume from the 150s scan in
TOST for all shorter scan durations (p<0.001). The infarct volume for onset to reperfusion
time >4.5-6h derived by the thresholds 7<CBF<13 mL∙min-1∙100g-1 was also equivalent to
the volume from the 150s scan in TOST for all shorter scan durations (p<0.01). For CBF<7
mL∙min-1∙100g-1, changing the scan duration from 150s to 120, 90, 60, and 40s decreased
infarct volume (mL) by (mean (95% CI)): -0.20 (-0.31 to -0.10), -0.13 (-0.28 to -0.02), 0.28 (-0.46 to -0.11), and -0.61 (-1.00 to -0.22) respectively, and resulted in 0 (0%), 0 (0%),
2 (3%), and 11 (17%) patients where the infarct volume changed by more than ±2mL
relative to their value from the 150s scan. When scan duration was decreased from 150s
to 120, 90, 60, and 40s the infarct volume (mL) for onset to reperfusion time >4.5-6h
defined by 7<CBF<13 mL∙min-1∙100g-1 changed by -0.29 (-0.52 to -0.05), -0.40 (-0.65 to
-0.15), -0.69 (-1.10 to -0.27), and -1.31 (-1.83 to -0.78) respectively, and resulted in 3 (5%),
3 (5%), 8 (12%), and 23 (35%) patients where the infarct volume changed by more than
±2mL relative to their value from the 150s scan. Figure 3.3 shows the 95% CIs, and range
of infarct volume changes relative to the volume from the 150s duration for both thresholds.
Table 3.1 shows the average infarct volume derived by each threshold for all scan
durations.
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Figure 3.3: Confidence intervals and range of volume differences relative to 150s scan
for CBF<7 mL∙min-1∙100g-1 and 7<CBF<13 mL∙min-1∙100g-1

Fig. 3.3: Average and 95% CIs (solid lines with markers), and range (dotted lines) of
differences in infarct volume relative to the 150s scan for CBF<7 mL∙min-1∙100g-1 (A) and
CBF<13 mL∙min-1∙100g-1 (B). Scan durations of 120, 90, 60, and 40s indicated by circles,
stars, squares, and diamonds respectively, and vertical dashed lines represent the
equivalence boundaries for the two-one-sided t-test procedures (±2mL). The volumes
derived by CBF<7 mL∙min-1∙100g-1 (p<0.001) and CBF<13 mL∙min-1∙100g-1 (p<0.01)
were equivalent to the 150s scan within ± 2mL for all shorter scan durations.
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Table 3.1: Average ± S.E. tissue volumes specified by CBF thresholds
Threshold
Infarct Volume at Each Scan Duration

CBF<7 mL∙min-1∙100g-1

7<CBF<13 mL∙min-1∙100g-1

150s

120s

90s

60s

40s

17.01 ±

16.81 ±

16.88 ±

16.73 ±

16.41 ±

1.91

1.92*

1.92*

1.91*

1.91*

37.06 ±

36.77 ±

36.66 ±

36.37 ±

35.75 ±

2.52

2.52*

2.53*

2.55*

2.55*

Table 3.1: Average infarct volumes for onset to reperfusion time <4.5h (cerebral blood
flow (CBF) <7 mL∙min-1∙100g-1), and onset to reperfusion time >4.5-6h (7<CBF<13
mL∙min-1∙100g-1) for each scan duration. Volumes that were statistically equivalent
(p<0.01), within ±2mL, as evaluated by two-one-sided tests, to the corresponding volume
measured from the 150s scan duration are indicated by an asterisk (*).
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3.4 Discussion
CTP is used in AIS to estimate the volume of infarct core and salvageable tissue at
admission to the hospital by applying thresholds to parameter maps, however the optimal
duration of CTP scans for AIS applications is not yet clear. The results of this study show
that CBV and Tmax calculated by GE Healthcare’s CTP4D software are dependent on scan
duration, whereas CBF calculations by this software, and therefore infarct volumes
quantified by previously derived CBF thresholds5, are independent of scan duration.
Truncation effects on median CBV and Tmax were most severe in the infarct ROI due to
delayed bolus arrival and slow contrast washout12,13, but significant truncation effects were
also seen in the ipsilateral-salvaged and contralateral ROIs. This agrees with results from
prior studies which found that truncation artifacts result in underestimated CBV in PWI15
and CTP scans16, and by extension, overestimated infarct volumes when CBV thresholds
are applied. Contrastingly, median CBF changed by only 1.4-6.5% of values from the 150s
scan, and similarly, time-dependent infarct volumes for onset to reperfusion time <4.5h
and >4.5-6h derived using CBF thresholds from scan durations ranging from 40 to 120s
were all equivalent to the volumes derived from the 150s scan in TOST procedures, within
±2mL (p<0.025). This means that when CBF thresholds are used to define the infarct core,
scan duration can be reduced to 40s without affecting treatment decisions made based on
infarct volume. For the 2-phase CTP protocol used in this study, this would remove the
entire 2nd phase and one-third of the 1st phase of the scan, or 13 out of 27 total time points.
This would have decreased radiation dose by ~48%, from ~5mSv26 to ~2.6mSv.
These results agree with prior CTP17 and PWI12 studies using deconvolution based
on standard singular value decomposition, oscillation-index regulated singular value
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decomposition12, and circular singular value decomposition17. These studies which found
CBF lesion volumes were independent of scan duration within the clinically relevant range
of scan durations (>40s)17, and that reversal of CBF lesions occurred in only ~3% of cases
when scan duration was decreased from 110 to 40s12. Although these studies established
the effect of truncation on CTP parameters and threshold-derived volumes, optimal
minimum scan durations that result in stable infarct/penumbra volume estimates were not
reported. A prior study by Kasasbeh et al, which used a research version of RAPID
(RAPID, iSchemaView, Menlo Park, CA), proposed calculating personalized minimum
scan durations depending on the arrival time and width of a patient’s venous output
function18. However, the shape of the venous output function is determined by venous
drainage of contrast from both ischemic and normal tissue. This could be an issue when
determining the optimal scan duration for AIS patients since it is likely that the arrival time
and width of the venous output function is not representative of the wash-in and washout
of contrast from ischemic tissue. Furthermore, calculating the patient’s optimal CTP scan
duration based on venous output function shape requires an additional pre-scan with a bolus
injection of contrast to measure the venous output function. This extra radiation dose is
counter-productive to using a shortened scan duration to limit radiation dose. In addition
to personalized scan durations, this study also recommended a population-based optimal
CTP scan duration of 70s, since infarct (relative CBF<30%) and penumbra (Tmax>6s)
volumes quantified with RAPID (iSchemaView, Menlo Park, CA) from a 70s scan
remained within ±10% of their respective volumes from a 90s scan18. The results of this
study suggest that if CTP4D (GE Healthcare, Waukesha, WI) is used for map computation,
and previously derived time-dependent CBF thresholds are used to determine tissue
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viability, then scan duration can be decreased to 40s, further reducing radiation dose,
without affecting tissue volumes by more than an average of ±2mL.
Relatively conservative equivalence bounds of ±2mL were chosen for TOST in this
study because they were equal to 10% of the smallest CTP-derived infarct volume used to
determine eligibility for endovascular therapy in the DAWN trial1.

In addition to

performing TOST we also reported the number of patients where infarct volumes
determined by each threshold changed by more than ±2mL relative to the 150s for each
scan duration. Although infarct volumes derived from 40s scans by the thresholds CBF<7
and 13 mL∙min-1∙100g-1 were equivalent to the 150s scan by TOST, there were 11 (17%)
and 23 (35%) patients respectively where the infarct volume derived by each threshold
changed by more than ±2mL relative to the 150s scan, however only 2 (3%) and 4 (6%)
patients experienced a change of greater than 4mL. Therefore, shortening scan duration to
40s may cause small infarct volume fluctuations in up to 35% of patients, but these
fluctuations are smaller than 4mL in most cases, and the average infarct volume change is
less than ±2mL.
Under- or over-estimation of the infarct or penumbra volume due to truncation is
problematic when mismatch criteria are used to determine treatment eligibility for AIS
patients. Penumbra volumes1 quantified by Tmax>6s could be underestimated at short scan
durations due to truncation, causing patients to be misclassified as ineligible for
endovascular therapy due to lack of salvageable tissue when they may have still benefited
from reperfusion. Similarly, infarct volumes27 determined by CBV<2mL/100g may be
overestimated with short scan durations, resulting in patients being incorrectly classified
as ineligible for endovascular therapy. Our results indicate that AIS triaging will not be
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affected by truncation artifacts for scan durations longer than 40s if maps are computed
with GE Healthcare’s CTP4D (CTP4D, GE Healthcare, Waukesha, WI) and previously
derived time-dependent CBF thresholds for infarction5 are used to define tissue viability.
CBF is determined by the upslope of the tissue time-density curve28, so unless
truncation affects this upslope, CBF is estimated relatively error free.

Based on

conservation of mass, CBV can be calculated as the area under the tissue time-density curve
divided by the area under the arterial input function29. With truncation, the area under the
time-density curve of ischemic tissue with delayed contrast wash-in and washout decreases
more rapidly than the area under the arterial input function resulting in underestimated
CBV. MTT is equal to the CBV divided by CBF, as required by the Central Volume
Principle30, therefore MTT also decreases with shorter scan durations. This also applies to
Tmax, since the software used in this study calculates Tmax as T0 plus half the MTT5. These
theoretical considerations explain why CBV and Tmax were affected by truncation artifacts
while CBF was not. It also explains why the limited truncation effect on CBF observed in
this study was similar to what was seen in studies using other deconvolution software
packages10,12, since CBF is dependent on the upslope of the tissue time-density curve,
regardless of what software is used to produce maps.
This study had several limitations.

As mentioned before, CTP maps vary

depending on the software used to compute them31, therefore optimal scan durations from
this study may not be directly applicable to other software packages. However, we expect
the general conclusion that CBF is relatively independent of scan duration, would remain
the same since it is calculated based on the upslope of the tissue time-density curve
regardless of software. CTP was acquired using a 2-phase protocol where images were
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acquired once every 15s in the second phase, this made it impossible to investigate scan
durations in between time points in the second phase. Analysis was also limited only to
scan durations longer than 40s since this is the shortest scan duration used clinically for
brain CTP. Lastly, this was a retrospective study with a relatively small group of patients.
The results of this study should be confirmed in a prospectively designed study with a
larger group of patients.

3.5 Conclusion
CBF remains constant and infarct volumes estimated using previously derived5
CBF thresholds are equivalent within ±2mL for scan durations ranging from 40 to 150s,
whereas CBV and Tmax decrease at shorter scan durations due to truncation errors. If these
CBF thresholds are used to determine treatment eligibility, then scan duration can be
decreased to 40s to reduce radiation dose to AIS patients by ~48% without triaging being
affected by truncation artifacts.
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Chapter 4

4

Reperfusion Assessed by CT Perfusion is a More
Specific and Accurate Predictor of Functional Outcome
than Modified Thrombolysis in Cerebral Infarction Score
in Ischemic Stroke Patients Treated with Intra-Arterial
Therapy

4.1 Introduction
IAT has become the standard of care for acute ischemic stroke patients with large
vessel occlusion after multiple clinical trials demonstrated superior efficacy compared to
thrombolysis alone1-6. More recently, results from the DEFUSE-3 and DAWN trials have
shown that IAT performed in patients selected by perfusion imaging within 16h7 and 24h8
post symptom onset is superior to medical management alone. One secondary outcome of
these trials was a mTICI score of 2b or 3 on post-procedural DSA, representing reperfusion
of 50-99% and 100% of the affected vascular territory respectively9. Although mTICI 2b/3
is a commonly accepted criterion for good reperfusion, ~15-20% of patients in the
treatment arm of earlier trials2-6 had a poor 90-day functional outcome (90-day mRS>2)
despite post-procedural mTICI scores of 2b/3; this number increased to ~30-35% in the
DEFUSE-3 and DAWN trials7,8. There is a need to better measure poor reperfusion after
IAT, to allow other treatment to be instituted as soon as possible. A more quantitative, less
subjective alternative to the mTICI score could be the percentage change in ischemic
volume from admission to shortly after IAT, calculated by applying thresholds for
ischemia10 to CTP maps obtained at admission and post-IAT11. Prior studies have shown
that post-procedural mTICI scores were independently associated with functional
outcome12-14, and improved outcome prediction accuracy15. However, relatively few
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studies have directly compared reperfusion assessed by follow-up CTP to post-procedural
mTICI scores as measures of post-IAT reperfusion, and as prognosticators of outcome after
IAT.
The objectives for this study were therefore: 1) to compare mTICI scores and a
CTP-based reperfusion metric and 2) to determine which of these two measures of
reperfusion was better associated with 90-day functional outcome. We hypothesized that
the CTP-based reperfusion metric would have a stronger association with 90-day functional
outcome than mTICI scores.

4.2 Methods
4.2.1

Patient Selection
The institutional review board approved this study and informed consent was

obtained from each patient contributing data to the study. Eligible patients were ischemic
stroke patients treated by IAT, received non-contrast CT, CT Angiography, and CTP at
hospital admission, and follow-up CTP approximately 24 hours post symptom onset,
functional evaluation 90-days post onset with mRS, and a complete record of demographic,
clinical and imaging variables, including mTICI score from post-procedural DSA.
Retrospective review of consecutive acute ischemic stroke patients admitted to the
Neuroscience Department of Azienda Ospedaliero-Universitaria di Ferrara (Italy) from
June 2008 to September 2015 identified 118 IAT-treated patients. Patients without onset
CTP (n=2), 24h CTP (n=11), 90-day mRS evaluation (n=2), or those with motion in either
onset or 24h CTP that was not amenable to correction with in-plane rigid registration (n=7)
were excluded, leaving 96 patients for the final patient cohort (Figure 4.1).
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Figure 4.1: Patient exclusion flow chart

Fig. 4.1: Flow diagram that highlights exclusions of patients after retrospective review of
all acute ischemic stroke (AIS) patients treated with intra-arterial therapy (IAT) between
June 2008 and September 2015. CTA indicates CT Angiography; CTP, CT Perfusion;
DSA, digital subtraction angiography; mRS, modified Rankin Scale; NCCT, non-contrast
CT.
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4.2.2

Imaging Protocol
Patients underwent non-contrast CT, CT angiography, and CTP at admission, DSA

after the IAT procedure concluded, and follow-up CTP at ~24h post admission (median
(IQR) = 25 (22-28) hours). All CT imaging were performed on a Lightspeed VCT scanner
(GE Healthcare, Waukesha, WI). Non-contrast CT and CT angiography imaging protocols
have been described previously16. Briefly, helical NCCT scans covered from the skull base
to the vertex with the following parameters: 120kV, 340mA, 4 x 5 collimation, 1s rotation
time, and table speed of 15mm/rotation16. CTA covering from the carotid bifurcation to
the vertex were acquired with the following parameters: 0.7mL/kg contrast (up to a
maximum of 90mL) injected at 4mL/s, 5-10s delay from injection to start of scanning,
120kV, 270mA, 1s rotation time, 1.25mm thick slices, and table speed of
3.75mm/rotation16. CTP scanning was initiated 5s after 40mL of CT contrast agent was
power-injected at 4mL/s into an antecubital vein. Most patients (n = 65) were scanned
using a 2-phase protocol without axial shuttle mode; volume (4cm coverage) acquired
every 0.5s for 50s in first phase, and every 15s for 150s in second phase, 80kV, 100mAs,
5mm slice thickness. Fifteen patients (n = 15) were scanned using a 2-phase protocol with
axial shuttle mode; volume (8cm coverage) acquired every 2.8s for 60s in first phase, and
every 15s for 135s in second phase, 80kV, 140mAs, 5mm slice thickness. Sixteen patients
(n = 16) were scanned with a 1-phase protocol without shuttle mode; volume (4cm
coverage) acquired every 0.5s for 50s, 80kV, 100mAs, 5mm slice thickness. All CTP
source images were reconstructed with the standard filter and DFOV of 25cm.
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4.2.3

Image Analysis
Admission CT angiography were reviewed by two neuroradiologists (AB and EF;

5 and 20 years of experience respectively) and assigned rLMC scores, clot burden scores,
and pre-treatment mTICI scores. Post-procedural mTICI scores were assessed on DSA.
The rLMC score has been described previously17; the degree of contrast opacification of
cerebral blood vessels is assessed in the six ASPECTS cortical regions, parasagittal anterior
cerebral artery territory, and basal ganglia and assigned a score of 0 (artery is not visible),
1 (artery is less prominent compared to contralateral side), or 2 (artery is equal or more
prominent compared to contralateral side) is assigned to each region. Scores can range
from 0-20, with increasing rLMC score indicating better collateral circulation status. The
clot burden score has also been described previously18; starting from a 10-point scale, 2
points were subtracted for lack of contrast opacification across the full cross-section in any
part of the supraclinoid ICA, proximal M1 segment, and distal M1 segment, and 1 point
was subtracted for each M2 branch, A1 segment and infraclinoid ICA. Clot burden scores
range from 0-10, with decreasing scores indicating greater thrombus extent.
CBV, CBF, and Tmax maps for admission and follow-up CTP studies were
computed by one author (EW; 5 years of experience) using commercially available delayinsensitive perfusion software (CTP4D, GE Healthcare, Waukesha, WI). In-plane patient
motion was corrected using an automated registration program included in the perfusion
software. The AIF and VOF were measured from regions of interest (ROIs) in the basilar
artery, and superior sagittal sinus respectively. If the AIF could not be measured from the
basilar artery, it was measured from an ROI in the contralateral anterior cerebral artery or
middle cerebral artery. The VOF was used to correct for partial volume averaging in the
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AIF, then CBF (mL∙min-1∙100g-1), CBV (mL/100g), and Tmax (seconds) maps were
computed by deconvolving the AIF from tissue TDCs. Dynamic images from the first pass
of contrast were averaged to create average maps, which were used to exclude
cerebrospinal fluid and skull using HU thresholds.
An ROI was drawn on the average image covering the ipsilateral hemisphere
(excluding ventricles and old infarct, if present), this ROI was superimposed onto cerebral
blood flow, cerebral blood volume, and time-to-maximum maps. Blood vessel pixels were
removed by applying thresholds to cerebral blood flow (>100 mL∙min-1∙100g-1), cerebral
blood volume (>8mL/100g) maps, and any remaining cerebrospinal fluid or skull was
removed by applying thresholds to the average image. Ischemic tissue volume was then
quantified using the threshold time-to-maximum >10s (derived in a previous study)10.
This process was repeated for admission and follow-up CTP studies to acquire admission
(Vadm), and 24h ischemic tissue volumes (V24h) for all patients. To quantify tissue
reperfusion measured by CTP, the reperfusion score (SCTP) was defined as the percentage
change in ischemic volume from admission to 24h follow-up11.

𝑆𝐶𝑇𝑃 =

[1]

𝑉𝑎𝑑𝑚 −𝑉24ℎ
𝑉𝑎𝑑𝑚

∙ 100%

The maximum value of the reperfusion score was 100% (V24h = 0mL), a reperfusion
score of 0% corresponds to no reperfusion between admission and 24h (Vadm = V24h), and
a negative reperfusion score indicates the ischemic tissue volume increased between onset
and 24h (V24h > Vadm).
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4.2.4

Statistical Analysis

4.2.4.1

Comparison of mTICI Scores to SCTP

Ordinal regression of post-procedural mTICI scores on SCTP was performed to
assess the association between reperfusion predicted by post-procedural mTICI scores and
reperfusion seen on follow-up CTP. One-way ANOVA and post-hoc t-tests with the
Bonferroni correction19 were used to compare the mean SCTP at different levels of postprocedural mTICI score. A one-sample t-test was also performed to determine if the mean
SCTP from mTICI 3 patients was significantly less than 100%, since mTICI 3 is meant to
indicate reperfusion of 100% of the affected vascular territory9.

4.2.4.2

Comparison of mTICI Scores and SCTP for Predicting
Functional Outcome

SCTP and other variables were compared between patients with good (mRS≤2) and
poor (mRS>2) outcomes using either independent samples t-test (continuous variable), or
Mann-Whitney U test (categorical variable). Variables that were significantly different
between good and poor outcome groups were included in a logistic regression model for
predicting outcome with backwards, stepwise elimination of variables.

Removal of

variables was based on the significance of the Wald statistic; the cut-off value for variable
removal was p>0.05.
ROC analysis was then performed to compare SCTP and the mTICI score in ability
to determine good outcome at 90 days. AUC was compared using methods described by
Hanley and McNeil20. Optimal thresholds for separating patients with good and poor
outcomes were defined using Youden’s J statistic21.

The corresponding sensitivity,

specificity, accuracy, PPV, and NPV of these optimal thresholds were determined.
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Statistical analysis was performed in SPSS version 20 (IBM Corporation, Armonk,
NJ), p<0.05 was considered significant. Values were reported as mean ± SE unless
indicated otherwise, error bars on figures are SE unless indicated otherwise in the figure
caption.

4.3 Results
4.3.1

Comparison of mTICI Scores to SCTP
Out of the 96 patients included, 48% (46/96) were female (mean age (±SD)

=70±11y) and 52% (50/96) were male (mean age (±SD) =69±11y). The most common
TOAST stroke subtype was cardioembolic (50/96), followed by atherothrombotic (36/96),
undetermined (8/96), and other (dissection) (2/96). Of the 96 patients, 32% (31/96)
received intravenous tissue plasminogen activator (IV-tPA). The number of patients with
post-procedural mTICI scores of 0, 1, 2a, 2b, and 3 were 17, 6, 5, 19, and 49 respectively.
The association between post-procedural mTICI score and SCTP was significant in
the ordinal logistic regression, but only 36% of the variation in SCTP was explained by the
post-procedural mTICI score (Nagelkerke R2=0.36, p<0.001). SCTP in patients with mTICI
scores of 2b (72.8±6.5%) and 3 (82.6±2.7) was significantly higher than in patients with
mTICI scores of 0 (27.0±12.2%) (p<0.001 for both mTICI 2b and 3) and 1 (16.7±6.8%)
(p≤0.001 and p<0.001 for mTICI 2b and 3 respectively) in post-hoc t-tests with the
Bonferroni correction. However, SCTP in patients with mTICI scores of 2a (67.7 ± 10.9%),
2b, and 3 were not significantly different from each other (p=1.00 for all pairwise
comparisons) (Figure 4.2). SCTP in mTICI 3 patients (82.6±2.7%) was also significantly
lower than the expected value of 100% (p<0.001).
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Figure 4.2: Mean SCTP at each level of post-procedural mTICI score

Fig. 4.2: Mean ± standard error reperfusion score (SCTP) at each level of the modified
thrombolysis in cerebral infarction (mTICI) score. Square brackets indicate lack of
significance (p>0.05) difference in SCTP between 2 or more levels of post-procedural
mTICI score.
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Interestingly, 26% (6/23) of patients with post-procedural mTICI≤1 had SCTP>50%,
even though mTICI scores of 0 and 1 are meant to indicate no reperfusion, with no flow
past the occlusion site and limited flow past the occlusion site respectively9. These patients
had SCTP ranging from 50.8-100% with an average of 84.0±8.3%, 4 of the 6 patients had
good 90-day functional outcomes. 18% (9/49) of patients with post-procedural mTICI
scores of 3 had SCTP<67%, despite mTICI 3 being defined as full reperfusion without any
flow defects9. These patients had SCTP ranging from 18.5-66.7% with an average of
50.0±6.0%, 6 of the 9 patients had poor 90-day functional outcomes (Figure 4.3).
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Figure 4.3: Ischemic lesion on 24h follow-up Tmax map for patient with postprocedural mTICI score of 3

Fig. 4.3: An example of the discrepancy between modified thrombolysis in cerebral
ischemia (mTICI) 3 and reperfusion score (SCTP) assessed on pre-treatment and 24h followup CT Perfusion (CTP). A-B) Frontal (A) and sagittal (B) views from the post-procedural
digital subtraction angiography (DSA) which was scored mTICI 3. C-D) Average image
(C) and time-to-maximum (Tmax) map (D) from 24h follow-up CTP showing a large
ischemic (Tmax>10s) lesion in the left MCA territory, SCTP for this patient was 18.5%.
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4.3.2

Comparison of mTICI Scores to SCTP for Predicting Functional
Outcome
Demographic, clinical, and imaging characteristics of the patients included in the

study are summarized in Table 4.1. The median admission rLMC scores (p<0.05), and
post-procedural mTICI scores (p<0.05) were higher for the good outcome group than the
poor outcome group, and the median admission NIHSS score (p<0.001) was lower in the
good outcome group than the poor outcome group. Onset to admission CT time was
unknown in 21 patients, among the other 75 patients, the mean onset to CT, and onset to
end IAT procedure times were not significantly different between good and poor outcome
groups. Average SCTP in the good and poor outcome groups were 82.3±3.3 and 51.5±5.8%
(p<0.001) respectively, and Average V24h in good and poor outcome groups were 14.9±3.2
and 37.7±5.1mL (p<0.001) respectively.
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Table 4.1: Demographic, clinical and imaging characteristics of the 96 patients
included in the study
Variable

Good Outcome
(mRS ≤ 2)

Poor Outcome
(mRS > 2)

p

Number of patients [n (% of total)]

45 (47)

51 (53)

NA

Age (y) [mean (SD)]

67.8 (11)

71.2 (11)

0.133

Sex [n (% female)]

25 (55.6)

21 (41.2)

0.162

Admission NIHSS score [median (IQR)]

13* (11-18)

20* (16-24)

<0.001

Admission rLMC score [median (IQR)]

14* (10-16)

11* (7-14)

0.010

Clot burden score [median (IQR)]

6 (4-7)

6 (3-7)

0.583

Admission mTICI score [median (IQR)]

1 (0-2)

0 (0-1)

0.094

Vadm (mL) [mean (SE)]

84.0 (6.1)

82.2 (6.2)

0.834

V24h (mL) [mean (SE)]

14.9* (3.2)

37.7* (5.1)

<0.001

SCTP (%) [mean (SE)]

82.3* (3.3)

51.5* (5.8)

<0.001

Post-procedural mTICI score [median (IQR)]

4* (3-4)

3* (1-4)

0.031

IV-tPA administration [n (% receiving IVtPA)]

18 (40.0)

13 (25.5)

0.283

Symptom onset to admission CT time (min)
[mean (SE)]

155.8⸸ (14.4)

146.2⸸ (11.3)

0.647

Admission CT to end procedure time (min)
[mean (SE)]

168.2 (11.2)

201.1 (12.3)

0.051

Symptom onset to end procedure time (min)
333.8⸸ (17.6)
347.9⸸ (16.5)
0.561
[mean (SE)]
Table 4.1: Demographic, clinical, and imaging characteristics of the patients in the good
(n=45), and poor (n=51) outcome groups. CT indicates computed tomography; IQR, interquartile range; IV-tPA, intravenous tissue plasminogen activator; min, minutes; mRS,
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modified Rankin Scale; mTICI, modified thrombolysis in cerebral infarction; n, number;
NIHSS, National Institute of Health Stroke Scale; p, p-value from independent samples ttest (parametric variables) or Mann-Whitney U test (non-parametric variables); rLMC,
regional leptomeningeal collateral; SCTP, reperfusion score; SD, standard deviation; SE,
standard error; V24h, 24h ischemic tissue volume; Vadm, admission ischemic tissue volume;
y, years.
* Significant difference (p<0.05) between good and poor outcome groups in an
independent samples t-test (continuous variables) or Mann-Whitney U Test
(ordinal/categorical variables).
⸸ 10 and 11 patients in the good and poor outcome groups respectively had unknown
symptom onset time and were excluded from the independent samples t-test.
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Variables that were significantly different between groups were included in a
logistic regression model to predict mRS outcome.

In stepwise elimination, post-

procedural mTICI was removed first, followed by V24h, and admission rLMC score, leaving
only SCTP and admission NIHSS to predict outcome with significance (p<0.001) (Table
4.2).
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Table 4.2: Logistic regression for predicting 90-day functional outcome based on SCTP
and admission NIHSS
B

SE

Wald

df

p

Odds
Ratio

95% CI for
Odds Ratio
Lower

Upper

SCTP

0.030

0.009

10.705

1

0.001

1.031

1.012

1.049

Admission
NIHSS

-0.137

0.043

10.825

1

0.001

0.872

0.804

0.946

Constant

0.048

0.964

0.003

1

0.960

1.049

Table 4.2: Summary of statistics for the variables that remained in the backwardelimination multivariate logistic regression for predicting 90-day outcome. B indicates
coefficients from the regression equation; CI, confidence interval; df, degrees of freedom;
NIHSS, national institute of health stroke scale; p, significance of the Wald test; SCTP,
reperfusion score; SE, standard error associated with B; Wald, Wald statistic used to test
the significance of B values.
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ROC curves for predicting outcome with SCTP, versus post-procedural mTICI score
as predictors of good outcome are plotted in Figure 4.4. The AUC for SCTP, and mTICI
score were, 0.717±0.053 (p<0.001), and 0.618± 0.057 (p<0.05) respectively. SCTP had a
significantly greater AUC than post-procedural mTICI (p<0.05).
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Figure 4.4: ROC curves for predicting good functional outcome based on S CTP and
post-procedural mTICI score

Fig. 4.4: Receiver-operator-characteristic (ROC) curves for reperfusion score (SCTP)
(solid), and post-procedural modified thrombolysis in cerebral ischemia (mTICI) score
(dashed), with the diagonal line of no discrimination (dotted).
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The optimal operating points for predicting good outcome corresponded to SCTP of
81.5%, and mTICI score of 2b. SCTP>81.5% had sensitivity, specificity, accuracy, PPV,
and NPV of 0.73 (33/45), 0.69 (35/51), 0.71 (68/96), 0.67 (33/49), and 0.74 (35/47)
respectively. The sensitivity, specificity, accuracy, PPV, and NPV of mTICI 2b/3 were
0.84 (38/45), 0.41 (21/51), 0.61 (59/96), 0.56 (38/68), and 0.75 (21/28) respectively. For
the logistic regression model, the optimal threshold for predicting good outcome
corresponded to: 0.03*(SCTP)–0.12*(admission NIHSS)>0.30. The sensitivity, specificity,
accuracy, PPV, and NPV of this threshold were 0.71 (32/45), 0.82 (42/51), 0.77 (74/96),
0.78 (32/41), and 0.76 (42/55). SCTP>81.5% had better specificity, accuracy, and PPV
compared to mTICI 2b/3, and the regression model had better specificity, accuracy, PPV,
and NPV than the SCTP or mTICI threshold alone (Figure 4.5).
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Figure 4.5: Sensitivity, specificity, accuracy, PPV, and NPV for regression model,
SCTP > 81.5% and mTICI 2b/3 for predicting functional outcome

Fig. 4.5: Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative
predictive value (NPV) of the optimal threshold for the regression model (black),
reperfusion score (SCTP) > 81.5% (grey), and modified thrombolysis in cerebral infarction
(mTICI) 2b/3 (white) for predicting good 90-day functional outcome.
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4.4 Discussion
In clinical trials 15-35% of IAT-treated patients with mTICI 2b/3 had poor
outcomes2-6. Some poor outcomes may have been due to reperfusion injury22 or lack of
salvageable tissue after long onset to recanalization times23; the discrepancy between
patients with mTICI 2b/3 and those with good outcome may have also resulted from mTICI
2b/3 not accurately reflecting near-complete/complete reperfusion.

Accurate

prognosticators of reperfusion will be important as more patients are treated after results
from DAWN and DEFUSE-3 showed the time window for IAT can be extended to 1624h7,8 in neuroimaging-selected patients.

This study’s objectives were to compare

reperfusion predicted by mTICI scores to reperfusion on admission and 24h CTP (S CTP),
and to compare mTICI score to SCTP as prognosticators of 90-day outcome.
Regarding objective 1, SCTP in patients with mTICI scores of 2b and 3 were
significantly higher than in the mTICI 0 and 1 groups, but there were no significant S CTP
differences between patients with mTICI scores of 2a, 2b, and 3, and ~18% of mTICI 3
patients had reperfusion of less than two-thirds of the affected tissue (SCTP<67%).
Regarding objective 2, only admission NIHSS and SCTP remained significant in a stepwise
logistic regression for predicting outcome. AUC was also significantly higher for S CTP
compared to mTICI score, and the optimal SCTP threshold derived in this study
(SCTP>81.5%) predicted good outcome with better specificity, accuracy, and PPV than
mTICI 2b/3.
Prior studies found post-procedural mTICI score12-15, and >90% reperfusion on
follow-up CTP were independent predictors of outcome24, but few studies have directly
compared prognostication of mTICI scores and follow-up CTP performed in the same
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patients. These results suggest visual assessment of post-procedural DSA can distinguish
patients with no reperfusion from patients with some reperfusion, but the degree of
reperfusion is difficult to judge, and mTICI 3 may not accurately represent complete
reperfusion on 24h CTP. As a result, low mTICI scores performed similarly to SCTP for
predicting poor outcome, but mTICI 2b/3 had poor specificity and PPV for predicting good
outcome compared to SCTP>81.5%, mostly because 18% of mTICI 3 patients were not fully
reperfused, leading to poor outcome. Incomplete reperfusion following IAT in mTICI 3
patients has been reported in prior studies finding tissue classified as salvageable on
admission CTP were often infarcted on follow-up, even when complete reperfusion was
achieved at an early time point25, and that infarct expansion between admission and 24h
occurred in ~35% of mTICI 3 patients26.
Perfusion on follow-up CTP may be overestimated by mTICI scores for several
reasons. The mTICI score requires neuroradiologists to assess perfusion of a 3D volume
based on 2D projections, potentially leading to overestimation when well perfused regions
overlap non-perfused regions; this is minimized when quantifying ischemic tissue on 3DCTP.

Furthermore, reperfusion of the affected territory on DSA is assessed by

presence/absence of capillary blush9.

Degree of capillary blush constituting good

perfusion, and size of the affected vascular territory may be subject to inter-rater
variability; inter-rater variability is minimized by the threshold-based SCTP used in this
study. Lastly, capillary plugging by leukocyte adhesion27, platelet accumulation28, and/or
lumen narrowing due to water accumulation in endothelial cells29 can lead to cerebral ‘noreflow phenomenon’, where capillary perfusion is impaired despite reperfusion of
upstream arterioles. Theoretically, no-reflow phenomenon would be better visualized
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using CTP than DSA, since CTP parameters are calculated directly from contrast
concentration changes in capillaries of each tissue voxel, as opposed to inferring tissue
perfusion based on presence/absence of capillary blush. This may explain why 9/49 mTICI
3 patients had SCTP≤66.7% (Figure 4.3), although this could have also been caused by reembolization between post-procedural DSA and 24h CTP30-32.
This retrospective study had limitations. Predicting poor outcome using 24h CTP
has limited clinical value, since most penumbral tissue has likely progressed to infarction
by this time, limiting effectiveness of additional interventions. Furthermore, time delay
between post-procedural DSA and 24h CTP introduced uncertainty, since the patients’
hemodynamic status may have changed between imaging sessions. For example, mean
SCTP in mTICI 0 patients was 27.0±12.1%; 35% (6/17) of these patients had SCTP>50%. In
these cases, disparities between mTICI score and SCTP were likely due to spontaneous clot
lysis32 between post-procedural DSA and 24h CTP. Similarly, 18% of mTICI 3 patients
(9/49) had SCTP<67%; differences between mTICI score and SCTP could have been due to
re-embolization between post-procedural DSA and 24h CTP, though studies suggest reembolization after IAT only occurs in ~10% of cases31-33. Another study, prospectively
designed to minimize time between post-procedural DSA and follow-up CTP, in a larger
group of IAT-treated patients could address these limitations.
In summary, post-IAT mTICI 2b/3 did not reflect reperfusion seen on follow-up
CTP, as a result, mTICI 2b/3 was not a specific marker of good outcome. S CTP derived
from pre- and post-procedural CTP scans was a better predictor of outcome than the
commonly used mTICI score.
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Chapter 5

5

Conclusions and Future Work
The introduction to this thesis describes the pathophysiology, treatment, and

medical imaging of AIS, with an emphasis placed on neuroimaging-based AIS triage and
management. As stated in the introduction, the main objective of this thesis was to identify
limitations and potential areas for improvement in CTP-based selection of AIS patients
who could benefit from IV t-PA or IAT and CTP-based outcome prognostication following
treatment. Specifically, a threshold for infarction after 3h of ischemia was developed using
multimodal imaging in a porcine model of AIS, the impact of scan duration on quantitative
CTP values and infarct volume derived by CBF thresholds was assessed, and the
association between reperfusion on follow-up CTP and functional outcome was determined
in IAT-treated AIS patients.
In this final chapter, major findings of this research and the implications for patient
care will be discussed, an outline of possible future studies that should follow this work
will be provided, and the major conclusions found from this work will be summarized.

5.1 Summary
5.1.1

Development of Porcine AIS Model and Derivation of 3h CBF
Threshold for Infarction
Animal models of AIS are necessary to determine CTP-based CBF thresholds for

different durations of ischemia because ischemia duration can be precisely controlled, a
factor which is impossible to control in the clinical setting.

Additionally, CBF

measurement and infarct delineation with gold standard imaging techniques can be
performed contemporaneously, eliminating uncertainties due to infarct expansion between
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the acute phase and follow-up imaging, which is often performed 1-7 days post symptom
onset in patients. As mentioned in Section 1.5, AIS models implemented in large animals,
such as pigs, are a better representation of human stroke because of their gyrencephalic
brain, and proportions of gray/white matter that are more similar to humans. However, the
rete mirabile makes commonly used intra-luminal procedures for inducing cerebral
ischemia impossible in pigs and other large mammals1, so most models require invasive
surgical procedures2,3 that make it difficult to maintain the animal at its basal physiological
state after stroke induction.
The ET-1 based porcine model of AIS presented in Chapter 2 requires only an
incision on the scalp and drilling of a small burr hole through the skull. This less invasive
approach is advantageous compared to craniectomy-based approaches used in prior
studies, which resulted in subarachnoid hemorrhage, ligature failure, and other technical
problems in ~40% of animals4; similar complications did not occur in any of the 11 animals
used in our study. Using this model, we were able to derive an absolute CBF threshold of
12.6 mL∙min-1∙100g-1 for infarction after 3h of ischemia, which agreed with the 3h CBF
threshold for infarction derived in the previously mentioned study using a more invasive
AIS model in monkeys (12 mL∙min-1∙100g-1)4.

5.1.2

Assessment of Scan Duration Effect on Quantitative CTP
Results
Despite more widespread use of CTP for AIS applications, the optimal CTP scan

duration for imaging the ischemic brain has yet to be comprehensively determined.
Shortening scan duration is beneficial to the patient because it decreases radiation dose.
However, if the CTP scan is too short to fully capture delayed contrast washout from

163

ischemic tissue it can cause errors in estimated CTP parameters5,6, which could cause overor underestimated threshold-derived infarct volumes, and therefore errors in AIS patient
triaging. Understanding how scan duration impacts CTP parameters and threshold-derived
infarct volumes is important to ensure that CTP-based triaging of AIS patients is accurate,
and reproducible between hospitals which may use different durations for brain CTP scans.
In Chapter 3 we determined the effect of scan duration on CBV, CBF, and T max
values, in normal and ischemic tissue, calculated by GE Healthcare’s commercially
available software (CTP4D, GE Healthcare, Waukesha, WI), for durations ranging from
40s to 150s. Optimal scan durations for two time-dependent CBF thresholds for infarction
previously derived by our group, which minimized radiation dose without infarct volumes
being affected by truncation artifacts, were also derived. We found that CBV and Tmax
were strongly dependent on scan duration, with median values decreasing by as much as
43% and 44% (relative to the median value from the 150s scan) respectively in ischemic
tissue, and 29% and 26% respectively in contralateral normal tissue, whereas CBF was
independent of scan duration, with the median value changing by only 1.4 to 6.5%.
Furthermore, infarct volumes derived by both time-dependent CBF thresholds for
infarction were found to be equivalent, within ±2mL, across the entire range of scan
durations investigated, meaning that scan duration can be decreased to 40s to minimize the
radiation dose to patients when CBF thresholds are used to estimate infarct volume. For
the 2-phase CTP protocol used in this study, this would remove the entire 2 nd phase and
one-third of the 1st phase of the scan, decreasing radiation dose by ~48%.
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5.1.3

Follow-up CTP as a Prognosticator of Functional Outcome in
IAT-Treated Patients
The degree of reperfusion following IAT is commonly assessed by applying the

mTICI scale to post-procedural DSA, with scores of 2b and 3 thought to represent nearcomplete and complete reperfusion of the previously ischemic tissue, respectively7
However, ~15-35% of patients in the treatment arm of clinical trials of IAT who had postprocedural mTICI scores of 2b/3 still went on to have poor functional outcomes8-14,
suggesting DSA may not accurately assess reperfusion after treatment. As neuroprotection
advances, accurately assessing reperfusion following IAT may become important for
identifying the patients most likely to benefit from neuroprotective drugs or therapies.
In Chapter 4, the accuracy of reperfusion assessed using mTICI scores on postprocedural DSA was investigated by comparison to a reperfusion score (SCTP) derived from
pre- and post-treatment CTP, and the two metrics were compared as predicters of 90-day
functional outcome in IAT-treated AIS patients. We found that SCTP was similar between
patients with post-procedural mTICI scores of 2a (67.7 ± 10.9%), 2b (72.8 ± .5%), and 3
(82.6 ±2.7%), revealing that post-procedural mTICI scores of 3 may not necessarily reflect
complete reperfusion on 24h follow-up CTP, and suggesting that although visual
assessment of DSA can differentiate patients with no reperfusion from those with some
reperfusion, it may not be able to accurately infer the degree of reperfusion. We also found
that SCTP was a significantly better predictor of functional outcome than post-procedural
mTICI score; the optimal SCTP threshold derived in the study (SCTP > 81.5%) predicted
good functional outcome with better specificity (0.69 versus 0.41), accuracy (0.71 versus
0.61), and PPV (0.67 versus 0.56) compared to mTICI 2b/3.

165

5.2 Experimental and Clinical Impact
Patients arriving at the hospital after the population-based time windows for IV tPA (4.5h) or IAT (6h), or those with unknown onset times were previously ineligible for
treatment, but results from recent clinical trials show that eligibility for IV t-PA in patients
with unknown onset time can be determined based on FLAIR-DWI mismatch15, and
eligibility for IAT can be determined with infarct/penumbra14 or clinical/imaging
mismatch13 assessed on CTP post-processed with RAPID, up to 24h post onset (detailed in
Chapters 1.3 and 1.4). This represents a significant step towards more personalized care
for AIS patients, but patient selection was not perfect in these trials (~50% of patients in
the IAT arm of DAWN and DEFUSE 3 had poor functional outcomes13,14); incorporating
time-dependent CBF thresholds for infarction could potentially improve patient selection
by providing more precise definition of the infarct core at different times since symptom
onset. Besides estimating admission infarct volume, applying multiple thresholds for
different ischemia durations from admission CTP-CBF maps could be used to predict the
increase in infarct volume over time. This could inform decisions regarding inter-hospital
transfer of patients being considered for IAT, by using the estimated increase in infarct
volume to predict whether the patient would still be eligible for IAT based on
infarct/penumbra or clinical/imaging mismatch criteria upon arrival. The animal study
described in Chapter 2 derived a CBF threshold for infarction after 3 hours of ischemia, if
similar thresholds were derived for a range of ischemia durations then this type of analysis
could become feasible. The findings of Chapter 2 are complemented by the findings of
Chapter 3, that quantitative CBF values from CTP are independent of scan duration, for
scans 40s or longer, and that infarct volumes derived by CBF thresholds are equivalent,
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within ±2mL, across scan durations ranging from 40s to 150s. Therefore, CTP scan
duration can be shortened to 40s to decrease radiation dose to patients by ~48%, without
truncation artifacts affecting AIS patient triaging decisions made based on infarct volumes
derived by time-dependent CBF thresholds.
Another important finding from this thesis is that reperfusion assessed on followup CTP is a more accurate indicator of 90-day functional outcome than mTICI scores
assessed on post-procedural DSA. Post-treatment reperfusion estimated by mTICI score
is commonly used to compare different revascularization therapies or IAT devices. Our
findings suggest that follow-up CTP should be used for these comparisons instead, since
follow-up CTP provides more accurate quantification of post-treatment reperfusion and is
more strongly associated with outcome than the commonly used mTICI score.

As

neuroprotective drugs and therapies continue to improve, these findings could take on even
greater importance as a method of identifying patients with incomplete reperfusion who
would most likely benefit from additional therapies.

5.3 Future Work
This thesis suggests several directions of further investigations into the applications
of perfusion imaging in AIS, some of these directions are discussed in this section.

5.3.1

Deriving CBF Thresholds for a Greater Range of Ischemia
Durations
The main limitation of the ET-1 porcine AIS model used in Chapter 2 was that the

cerebral ischemia in the distal MCA territory was not highly reproducible between animals
and did not mimic LVO in patients, this was likely because ET-1 was not injected in the
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immediate vicinity of the proximal MCA in all cases. With improved localization of the
MCA using TDCs from dynamic CTP images (Figure 5.1), it should be possible to inject
ET-1 close to the origin of the MCA, thus producing a proximal constriction more similar
to LVO. Furthermore, the ischemic territory will be more reproducible, and we will be
able to extend the ischemia duration well beyond 3h with repeated ET-1 injections at the
same site. This would allow absolute CBF thresholds for infarction to be derived for a
greater range of ischemia durations using a similar procedure to what was used in Chapter
2 but changing the duration between the ET-1 injection and the start of

18

F-FFMZ PET

imaging. This could be performed in several groups of animals, each with a different time
interval between ET-1 injection and infarct imaging, or alternatively, FMZ labelled with
11

C (half-life ~20 minutes) could be used, since the shorter half-life could allow the infarct

to be delineated at multiple time points in the same animals.
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Figure 5.1: Localization of MCA in porcine AIS model with dynamic images from
CTP

Fig. 5.1: Targeting the right MCA for ET-1 injection to induce stroke. (A) CTP image at
time of maximal contrast enhancement in arteries and proximal veins; (C) same image as
(A) but in bone window to show the anatomical landmarks of the skull and carotid rete
mirabile; (B) TDCs from ROI 1-6 including the R ICA, MCA and proximal veins.
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5.3.2

Using PS to Identify Patients at Increased Risk of
Hemorrhagic Transformation
To further improve CTP-based patient selection for IV t-PA or IAT, methods for

identifying patients at increased risk of hemorrhagic transformation could be developed
based on assessing BBB permeability using PS maps from admission CTP. PS thresholds
could be established based on the average PS within the infarct, or the volume of tissue
within the infarct with elevated PS (relative to the contralateral side).

170

Figure 5.2: Elevated PS in patient with hemorrhagic transformation after IAT

Fig. 5.2: Average image (left), CBF map (middle), and PS map (right) from admission
CTP of a 46-year-old, male patient with occlusion of the M1 segment of the right MCA,
who was treated with IAT but had grade 2 parenchymal hematoma on 7-day follow-up
imaging. Elevated PS is seen throughout the ischemic tissue in the right MCA territory on
admission CTP.
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5.3.3

Assessment of Post-IAT Reperfusion using ‘DSA Perfusion’
Maps
In Chapter 4 we found that follow-up CTP provides more accurate assessment of

post-thrombectomy reperfusion compared to post-procedural mTICI scores assessed on
DSA and was a more accurate predictor of functional outcome. However, performing
follow-up CTP requires transferring the patient from the angiography suite to a CT scanner,
it would be more advantageous if there was a similar method of assessing reperfusion
which could be performed in the angiography suite. Our group has recently created
software capable of producing perfusion maps from dynamic DSA acquisitions (Figure
5.3). This would provide a more quantitative, less subjective alternative to the mTICI score
for assessing reperfusion on post-procedural DSA. If the accuracy for predicting functional
outcomes using this new technique is similar to what was observed using follow-up CTP
in Chapter 4, then ‘DSA perfusion’ maps could improve outcome prediction after IAT
without the need for additional follow-up CTP to be performed.
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Figure 5.3: Blood flow maps derived from DSA (anterior-posterior view)

Fig. 5.3: Blood flow maps derived from DSA before (left) and after thrombectomy (right),
shown in the anterior-posterior view. Black arrow in pre-IAT CBF map shows occlusion
of MCA resulting in ischemic downstream tissue. After IAT, flow in the MCA and
downstream tissue was been restored.
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5.4 Conclusion
In summary, the significant findings of this thesis include:
1. As shown in a porcine model of AIS, tissue with CBF < 12.6 mL∙min-1∙100g-1 will
progress to infarction after 3h of ischemia.
2. CBV and Tmax values computed with commercially available CTP software depend
on the duration of the CTP scan, whereas CBF is independent of the scan duration.
By extension, infarct volumes derived by time-dependent CBF thresholds are
equivalent, within ±2mL, over a range of scan durations from 40s to 150s.
3. Reperfusion assessed on follow-up CTP is a more accurate predictor of 90-day
functional outcome in IAT-treated AIS patients than mTICI scores from postprocedural DSA.
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Appendices
Appendix A: Supplementary Figures for Chapter 2
Figure A.1: CBF Histograms for each Animal

Fig. A.1: Frequency distributions of CBF values from infarct (blue) and
penumbra/oligemia tissue (yellow) for each of the 6 animals from Chapter 2.
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Figure A.2: 18F-FFMZ PET and CBF maps from Animal 1

Fig A.2: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 1.
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Figure A.3: 18F-FFMZ PET and CBF maps from Animal 2

Fig A.3: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 2.
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Figure A.4: 18F-FFMZ PET and CBF maps from Animal 3

Fig A.4: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 3.
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Figure A.5: 18F-FFMZ PET and CBF maps from Animal 4

Fig A.5: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 4.
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Figure A.6: 18F-FFMZ PET and CBF maps from Animal 5

Fig A.6: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 5.
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Figure A.7: 18F-FFMZ PET and CBF maps from Animal 6

Fig A.7: 18F-FFMZ PET and CBF maps from 30, 60, and 120min post ET-1 injection in
slice with the largest extent of infarct in Animal 6.
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